 
 Masonic Cancer Center, University of Minnesota 
Cancer Experimental Therapeutics Initiative (CETI) 
 
 
Study of FT538 in Combination with Daratumumab in  
Acute Myeloid Leukemia 
CPRC #2020LS114 
MT2020-33 
IND # [ZIP_CODE] 
 
Principal Investigator/IND Sponsor: 
Joseph Maakaron, MD  
Division of Hematology/Oncology/Transplantation 
Medicine Hematology Office 
[ADDRESS_1176684] SE MMC 480  
Minneapolis, MN [ZIP_CODE] 
Phone: [PHONE_8858] (Administrative phone) 
Email: [EMAIL_16046] 
 
 
Collaborators: 
Daniel Weisdorf, MD 
Margaret L. Macmillan, MD (pediatrics) 
Jeffrey S. Miller, MD* 
David H. McKenna, Jr., MD* 
*Will not consent patients to enroll on study 
 
 
Biostatistician: 
Ryan Shanley, MS 
University of Minnesota 
 
 
Version Date:  
May 8, 2023 
 
 
Confidential  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 2 of 79 MT2020-33 Revision History 
Revision 
# Version Date Revision Details Consent 
Revision 
 Oct 28, 2020 Original to FDA n/a 
 Dec 7 2020 Original to CPRC 
Synopsis , Section 3 , Section 4 , and Section 7 : In response to 
the clinical IR dated Nov 27 2020 – Delay pediatric enrollment 
until a minimum of 6 adults are treated on this study and/or the 
combination arm on Fate’s FT538-101 and safety data is 
submitted to the FDA for their review and permission to 
proceed with the enrollment of children is received. 
Minor edits and clarifications in Section 8  and Section 10 . n/a 
 Jan 27 2021 In response to CPRC stipulations – updates to Section 12 and 
other relevant protocol sections (increasing expected 
enrollment to 17 from 15 patients). 
Updates from CCPM: 
• Schema: delete Day +[ADDRESS_1176685] previously missed. 
• Synopsis, Schema, Section 3, Section 5: Correct intra cohort 
enrollment plan from no staggering required to “ A minimum 
of [ADDRESS_1176686] and 
the 2nd patient in 3 patient cohorts .” to match language in 
Section 12. 
• Synopsis, Section 4.1: prior allogenic HSCT permitted but 
remove reference to relapse  
• Synopsis, Section 4.3.13: remove relapse contingency for 
exclusion for allogeneic HSCT within previous 90 days 
Other general updates: 
• update protocol that DARA will be purchased for the study,  
• delete reference of Monday as 1st day of FT538 through-out 
while retaining Monday as Day 1 on an example calendar in 
Section 6. 
• update LTFU study number to CPRC 2020LS220, remove 
the “0” from the MT number to read MT2020 -33 
• update Section [ADDRESS_1176687] Section 
numbers for DLT and SRs 
• other minor edits/updates throughout n/a 
1 Mar 11 2022 • Section 6 introduction and Section 6.4 - permit the use of 
hydroxyurea during study treatment as needed for the control 
of peripheral blood blasts and/or white blood count. 
• Update title page to reflect [CONTACT_846392] also is the IND 
sponsor and change in statistician, delete Key Study Staff 
Contact [CONTACT_846361] 2 as no longer needed.  
• Section 11.3 – list [CONTACT_846392] as the IND S/I, add Dr. 
MacMillan as pediatric physician. 
Minor changes/edits identified during and since the study 
initiation visit (SIV) in Aug 2021:  
• Update abbreviation table with S[LOCATION_003]R and S/I simplify 
FT538 
enrollment 
plan and 
clean-up 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 3 of 79 MT2020-33 Revision 
# Version Date Revision Details Consent 
Revision 
• Schema, Section 3 -Simplify how enrollment plan is written 
without change to content. 
• Synopsis, Section 4.2.3 – update KPS/Lansky lower eligibility 
limit from ≥80 to ≥70  (from SIV) 
• Synopsis, Section 4.2.4 – clarify lab work is done within 14 
days prior  to start of study treatment, delete cardiac 
requirement as addressed in exclusion criteria Section 4.3.4. 
• Section 6.1 – clarify monitoring section for daratumumab 
• Section 6.5 - expand duration of treatment section to include 
end of treatment assessment with reminder stoppi[INVESTIGATOR_846335] 42. 
• Section 6.6 - clarify follow-up for disease response/survival  
• Section 8 – clarify the timing of the end of DLT/EOT 
assessment as both are scheduled for Day 29 
• Section 8.1 – eliminate ICANS assessment at screening and 
Day -5 as neuro changes are associated with FT538 
• Section 8.2 – add yellow top tube baseline safety samples for 
Fate in the event a patient had previously received a Fate 
product that used a lentivirus vector in manufacturing 
• Section 10.1 – remove the definition of protocol deviation as 
defined only applicable to studies covered by [CONTACT_544194]  
• Section 10.2 – clarify any event meeting the definition of 
serious must be recorded as an AE, clarify the reporting of 
abnormal lab values and assessments 
• Appendix III – CY/FLU adverse events – replace section 
wording to match Fate Therapeutics’ sponsored trials  
• Through-out the protocol delete the CPRC number for the 
LTFU protocol as being replaced by a master LTFU protocol 
• Other minor edits/clarifications 
 Nov 24 2022 Rationale for current amendment: please see section 2.5, 
bottom of page 18.  
• Synopsis, schema, section 2.5, section 6.2- Update to 
lymphodepletion fludarabine days given (-6 to -2) and 
cyclophosphamide dosing (changed from 300mg/m2 to 60 
mg/kg), spacing between subjects in final cohort 
• Section 3 – updates to fast-track cohort spacing between 
subjects in expansion  
• Section 6 – updated table in treatment plan to reflect updated 
LD 
• Section 6.3.1 – minor clarification to DLT events 
• Section 7 - minor clarification to ensure proper classification 
of febrile neutropenia events per protocol 
• Section 8.1 – updated clinical Schedule of Treatments to 
reflect day -6 and day -2 
• Section 8.2 – updated Research Related Tests and 
Procedures to include bone marrow biopsy at day +3 (–1 
day) 
• Section 12.1-updated fast-track cohort spacing in statistics 
section to reflect changes in section 3  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 4 of 79 MT2020-33 Revision 
# Version Date Revision Details Consent 
Revision 
 03/23/2023 Synopsis, schema, section 6.1 – revised to reflect that 
daratumumab reduced to one dose from four 
Section 2.5 – revised to address reduction in daratumumab 
Section 4.2.5 – revised to update contraceptive use guidelines 
Section 8.1 and 8.2 – revised to remove days [ADDRESS_1176688] updated treatment schedule/adjust research blood 
draws accordingly 
Appendix VI: added to document previous study schema 
Minor corrections of typos/formatting throughout 
Consent: revised to include language re: risk of 
xenotransplantation required by [CONTACT_8415] Y 
 04/20/2023 Section 12.1: fixed typo in paragraph 3, dose level 3 is 1x109 
cells 
Appendix V and VI: per CPRC recommendation updated titles 
with more information re: previous versions n 
 05/08/[ADDRESS_1176689]. n 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 5 of 79 MT2020-33 TABLE OF CONTENTS 
 
Key Abbreviations .......................................... ................................................... ....................... 7 
Protocol Synopsis .......................................... ................................................... ....................... 8 
Study Schema........................................... ................................................... .......................... 12 
1 Objectives ......................................... ................................................... ........................... 14 
1.1 Primary Objective ................................... ................................................... .............. 14 
1.2 Secondary Objectives ....................................... ................................................... .... 14 
1.3 Correlative Objectives ...................................... ................................................... .... 14 
2 Background and Significance ............................... ................................................... ........ 14 
2.1 Introduction and Disease Under Treatment ......................... .................................... 14 
2.2 Natural Killer Cells ................................... ................................................... ............. 15 
2.3 FT538 ........................................... ................................................... ........................ 17 
2.4 The Role of Daratumumab and Use of subQ DARZALEX FASPRO ............. ........... 18 
2.5 Lymphodepletion with Cyclophosphamide and Fludarabine ............................ ........ 19 
2.6 Study Rationale ....................................... ................................................... ............. 20 
2.7 Rationale to Include Pediatric Patients 12 Years Old or Older ............ ..................... 20 
3 Study Design ......................................... ................................................... ...................... 21 
4 Patient Selection ......................................... ................................................... ................. 24 
4.1 Disease Specific Inclusion Criteria ............................. .............................................. 24 
4.2 Inclusion Criteria ................................... ................................................... ................ 24 
4.3 Exclusion Criteria ...................................... ................................................... ........... 25 
5 Patient Screening and Enrollment ............................... ................................................... . 26 
5.1 Registration with the Masonic Cancer Center Clinical Trials Office ....... ................... 26 
5.2 Patient Enrollment and Dose Cohort Placement ..................... ................................. 26 
5.3 Patients Who Do Not Begin Study Treatment ........................... ............................... 26 
6 Treatment Plan ........................................ ................................................... .................... 27 
6.1 Daratumumab Administration Guidelines ............................. .................................... 27 
6.2 Cyclophosphamide/Fludarabine Lymphodepletion Guidelines ....................... .......... 29 
6.3 FT538 Administration ...................................... ................................................... ..... 29 
6.4 Permitted and Prohibited Concomitant Medications/Therapi[INVESTIGATOR_014] ................ ................ 32 
6.5 Duration of Treatment ................................. ................................................... .......... 33 
6.6 Follow-Up for Disease Response and Survival (Duration of Study Participation) .... . 33 
6.7 Continuation of Follow-Up via a Separate Long-Term Follow-Up Protocol ............ ... 34 
7 Recommended Management Guidelines for Specific Adverse Events Associated with 
FT538 ............................................. ................................................... .................................... 34 
7.1 Infusion Related Reaction Associated with FT538 ........................ ........................... 36 
7.2 DMSO Related Risks ..................................... ................................................... ....... 37 
7.3 Infection ........................................... ................................................... ..................... 37 
7.4 Cytokine Release Syndrome (CRS) or CRS-Like Symptoms ................. .................. [ADDRESS_1176690] Disease ............................. ............................................... 44 
7.7 Tumor Lysis Syndrome (TLS) ................................ .................................................. 45 
7.8 Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections ...... . 46 
7.9 Immunogenicity ...................................... ................................................... .............. 46 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 6 of 79 MT2020-33 8 Schedule of Treatment, Tests, and Procedures .................... .......................................... 47 
8.1 Required Clinical Care Evaluations ........................... .............................................. 48 
8.2 Research Related Tests and Procedures .................................. .............................. 50 
9 Study Agents ....................................... ................................................... ........................ 51 
9.1 FT538 ........................................... ................................................... ........................ 51 
9.2 Daratumumab ........................................... ................................................... ............ 52 
10 Adverse Event Monitoring, Documentation, and Reporting .............. ............................... 55 
10.1 Adverse Event Terminology ................................ ................................................... .. 56 
10.2 AE Monitoring and Event Documentation Requirements ............... .......................... 57 
10.3 SAE Documentation and Reporting ........................ ................................................. 5 9 
10.4 Dose Limiting Toxicity and Excessive Toxicity (Stoppi[INVESTIGATOR_134145]) Documentation 
and Reporting Requirements .................................. ................................................... ...... 59 
10.5 Documentation of Death and Reporting Requirements ............. ............................... 59 
10.6 Expedited MCC Reporting Requirements ........................ ........................................ 60 
11 Study Data Collection and Monitoring ........................... .................................................. 60 
11.1 Data Management ....................................... ................................................... ......... 60 
11.2 Case Report Forms ................................... ................................................... ........... 61 
11.3 Data and Safety Monitoring Plan (DSMP) ...................... .......................................... [ADDRESS_1176691] Retention ..................................... ................................................... ............ 62 
12 Statistical Considerations ................................ ................................................... ............. 62 
12.1 Study Design, Objectives and Endpoints ....................... .......................................... 62 
12.2 Statistical Analysis .................................... ................................................... ............ 64 
12.3 Sample Size .......................................... ................................................... ............... 64 
12.4 Monitoring Guidelines (Early Study Stoppi[INVESTIGATOR_1869]) ................... ............................. [ADDRESS_1176692] of the Study ................................ ................................................... ................... 66 
13.1 Good Clinical Practice .................................... ................................................... ...... 66 
13.2 Ethical Considerations .................................. ................................................... ........ 66 
14 References ........................................... ................................................... ....................... 67 
Appendix I – Karnofsky Performance Status Scale/Lansky Play –Performance Scale ............ 70 
Appendix II – [LOCATION_001] Heart Association (NYHA) Classification ................... ....................... 72 
Appendix III - Risks Associated with Cyclophosphamide and Fludarabine ............... .............. 73 
Appendix IV – European LeukemiaNet (ELN) Response Criteria in Acute Myelogenous 
Leukemia ............................................. ................................................... ............................... 75 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176693] hematopoietic stem cell transplantation 
IB Investigator’s Brochure  
ICANS immune cell associated neurotoxicity syndrome 
ICH International Conference on Harmonization 
rHuPH20 recombinant human hyaluronidase PH20 
IL-15RF IL-[ADDRESS_1176694] 
RECISTv5 Response Evaluation Criteria in Solid Tumors version 5 
rhIL-15 Recombinant human interleukin-15 
SAE serious adverse event 
S/I Sponsor/Investigator 
SOC standard of care 
SR stoppi[INVESTIGATOR_846336] #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 8 of 79 MT2020-33 Protocol Synopsis 
Study of FT538 in Combination with Daratumumab in Acute Myeloid Leukemia 
CPRC #2020LS114 / MT2020-33 
Study Design: This Phase I open-label dose escalation study is conducted in two stages with a primary  endpoint to 
identify the maximum tolerated dose (MTD) of FT538 when administered with daratumumab in patients  
12 years of age and older with advanced acute myeloid leukemia (AML) and related myelo id diseases.  
FT538 is an off-the-shelf product comprised of allogeneic natural killer (NK) cell immu notherapy lacking 
CD38 and expressing hnCD16 and IL-15RF. Daratumumab is a targeted therapy (IgG1k human 
monoclonal antibody) that targets CD38. 
FT538 is administered once a week for 3 consecutive weeks (Day 1, Day 8, and Day 15). Up to [ADDRESS_1176695] FT538 cell infusion to determine disease free 
survival, treatment related mortality, and time to and incidence of relapse.  
Enrollment 
Plan: There are five potential FT538 Dose Levels (DL). The starting dose is FT538 1x108 cells per dose with a 
lower safety dose of 5x107 if needed (Dose Level -1). The subsequent planned FT538 cohorts are 
3x108, 1x109, and 1.[ADDRESS_1176696]-track design (1 patient per dose cohort)  
Start at Dose Level 1 (DL1), enroll 1 patient per dose cohort separated by 28 days (DLT period) until 
the:  
• 1st pre-defined adverse event defined as any Grade 3 non-hematologic AE within 72 hours of a 
FT538 infusion  
• and the patient completes the 28 day DLT period with no DLT- Activate Stage 1 Step 2  
OR  
• 1st DLT event within [ADDRESS_1176697] dose of FT538 as defined in the Schema and in Section 
6.3.1 - Activate Stage 2 (Stage 1 Step 2 is not used)  
OR 
• 10 patients are treated at the Dose Level 4 (This completes enrollment - Stage 1 Step 2 and Stage 
2 are not used) 
o If the first patient at dose level [ADDRESS_1176698] patient, subsequent 9 subjects may enroll without staggering  
 
STAGE 1 STEP 2 Expand current Dose Level and subsequent DLs to 3 patients  
The cohort size increases from 1 to 3 patients to explore the occurrence of an AE. Two  additional 
patients added to the current cohort without staggering. Continue dose escalation until: 
• 1st DLT event as defined in the Schema and Section 6.3.1 - Activate Stage 2  
OR  
• 10 patients are treated at the Dose Level 4  (This completes enrollment and Stage 2 is not used.) 
o For Dose Level [ADDRESS_1176699]. If no DLT events within 
monitoring period, successive subjects may enroll without staggering  
 
STAGE 2 Continual Reassessment Method (CRM) at the 1st DLT  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176700] patient in a cohort reaches Day 29 (end of DLT peri od). 
The MTD is identified by [CONTACT_134186]: (1) the total Stage 2 maximu m sample 
size of 25 is exhausted or (2) 10 consecutive patients are enrolled at the same FT538 dose.  
Investigational 
Products: Fate FT538  
Daratumumab and hyaluronidase-fihj (DARZALEX FASPRO ™) for subcutaneous administration  
Long-Term 
Follow-up: As FT538 is an engineered cellular product long-term follow-up (LTFU) is recommended by [CONTACT_38785] A for 
any patient receiving at least one dose of FT538. Clinical safety information is c ollected at post-
treatment follow-up visits or through telephone calls, medical record review, and/o r e-mail/mail for up to 
15 years as described in the companion LTFU protocol. Consent to LTFU is required for participa tion in 
this treatment study. 
Study 
Rationale: FT538 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master human-
induced pluripotent stem cell (iPSC) line with the following engineered elements: a)  deletion of the gene 
encoding CD38 (i.e., CD38 knockout to overcome killing of the infused FT538 product by 
[CONTACT_755541]); b) high-affinity, non-cleavable CD16 receptor (hnCD16) to bind daratumumab; and c) 
interleukin (IL)-15/IL-15 receptor alpha fusion protein (IL-15RF) to enhance survival and activity  of NK 
cells after adoptive transfer. The engineered features of FT538 are designed to result in increased 
activity against target tumor cells as monotherapy and when combined with monoclonal antibodi es 
(mAbs) that can mediate antibody-dependent cellular cytotoxicity (ADCC). Daratumum ab is a targeted 
therapy (IgG1k human monoclonal antibody) that targets CD38.  While daratumumab is FDA approved 
for treatment of multiple myeloma, it is not approved for AML. However, a majority of AML blasts 
express CD38 and daratumumab can mediate antibody dependent cellular cytotoxicity by [CONTACT_33152].  
Primary 
Objective  To determine the maximum tolerated dose (MTD) of FT538 when given in combination with 
daratumumab in the treatment of acute myeloid leukemia. 
Secondary 
Objectives:  • To obtain preliminary estimates of efficacy as measured by [CONTACT_846362] e response (CR + CRi) 
assessed by [CONTACT_2006] 28, the primary trial endpoint based on the 2017 Europea n LeukemiaNet (ELN) 
response criteria ( Döhner 2017 )  
• Estimate the overall response rate (ORR) at 1 year of follow-up 
• Estimate disease free survival (DFS) and overall survival (OS) at 1 year of fol low up 
• Determine safety of this combination as outlined by [CONTACT_410783] (AEs) based on 
CTCAE v5.0 
Correlative 
Objectives:  • Change in level of expression of CD38 on leukemic blasts and normal tissue over time as 
determined by [CONTACT_398]38 measurement by [CONTACT_846363] 
• Determination of the PK of FT538 in the peripheral blood and marrow 
• Clinicopathological correlates of efficacy (level of CD38 expression, cytogenetics an d molecular 
classification of the disease) 
• Clinicopathological correlates of safety (level of CD38 expression, cytogenetics and molecular 
classification of the disease) 
• Characterization of the kinetics of changes in CD38-expressing host i mmune cell populations 
including NK, Treg and MDSCs after exposure to daratumumab 
Disease 
Related 
Inclusion: Acute myeloid leukemia relapsed/refractory after 2 lines of therapy with CD38 expression  
• CD38 expression is defined by ≥20% of malignant cells with CD38 expression by [CONTACT_846364] (must be within 30 days of study enrollment).  
• Relapsed/refractory is defined as failure to achieve at least a Morphological Leukemia Free Stat e 
(MLFS) or reverting from MLF i.e. any level of blasts detected by [CONTACT_4133].  
• Lines of therapy are defined as: 
o One cycle of Intensive induction chemotherapy such as 7+3, 5+2, MEC, FLAG, FLAG-Ida, or 
CLAG – small molecule inhibitor 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 10 of 79 MT2020-33 o Four weeks of HMA-based induction – small molecule inhibitor 
o Hematopoietic stem cell transplantation (HSCT), must be >[ADDRESS_1176701] 
o Gemtuzumab Ozogamicin 
o LDAC + glasdegib 
o Biomarker-specific targeted agents (FLT3 inhibitors, IDH1/2 inhibitors, others if availab le) 
o Other treatments maybe considered after discussion with the PI 
[INVESTIGATOR_846337]:  • Age 12 years or older at the time of consent 
• Weight ≥ [ADDRESS_1176702] pre-dosed packaging 
• Karnofsky performance status of 70-100% for age ≥16 years, Lansky play score  of 70-100 for age 
<16 years 
• Evidence of adequate organ function within 14 days prior to starting study treatment defined as: 
o Estimated Glomerular Filtration Rate (estimated creatinine clearance) ≥50 mL/minute  
o Total bilirubin ≤ 5 × upper limit normal (ULN), not applicable for patients with Gilbert’s syndrome  
• AST ≤3 × ULN and ALT ≤ 3 × ULN, not applicable if determined to be directly due to underlying 
malignancy Sexually active women of child-bearing potential and males with female partners of  
childbearing potential must agree to use must use a highly effective form of contracepti on as detailed 
in Section 4.2.5  
• Must agree to and sign the consent for the companion Long-Term Follow-Up study to fulfill the  FDA 
required [ADDRESS_1176703]   
• Patient ≥18 years  provides voluntary written consent prior to the performance of any research related 
procedure. Minors (<18 years) provide voluntary written assent with the parent/guardia n signing the 
treatment consent prior to the performance of any research related procedure.  
Key Exclusion 
Criteria:  • Diagnosis of acute promyelocytic leukemia (APL)  
• Pregnant or breastfeeding, Menstruating females of child-bearing potential must have a neg ative 
pregnancy test within 14 days of study treatment start 
• Known allergy to any of study drugs or their components 
• Clinically significant cardiovascular disease including any of the following: myocardia l infarction within 
[ADDRESS_1176704] study treatment; unstable angina or congestive heart failure of [LOCATION_001] Heart 
Association Grade 2 or higher or cardiac ejection fraction <40% 
• Any known condition that requires systemic immunosuppressive therapy (> 5mg prednisone dai ly or 
equivalent) during the FT538 dosing period ([ADDRESS_1176705] 
dose) excluding pre-medications – inhaled and topi[INVESTIGATOR_12977] 
• Receipt of any biological therapy, chemotherapy, or radiation therapy, except for palliative purpos es, 
within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy  
within [ADDRESS_1176706] dose of daratumumab.  
• Known active central nervous system (CNS) involvement or treated CNS disease that has not cl eared. 
If prior disease- related CNS involvement, then must have completed effective treatment of  their CNS 
disease  
• Non-malignant CNS disease such as epi[INVESTIGATOR_002], CNS vasculitis, or neurodegenerative disease  or 
receipt of medications for these conditions in the 2-year period leading up to study enr ollment   
• Clinically significant untreated/uncontrolled infection 
• Live vaccine <6 weeks prior to start of lympho-conditioning 
• Known seropositive for HIV or known Hepatitis B or C infection with detectable viral load by [CONTACT_954] 
• Prior solid organ transplant 
• Allogeneic HSCT within previous 90 days  
• Active GVHD requiring systemic immune suppression within 14 days prior to enrollment 
• Presence of any medical or social issues that are likely to interfere with study conduct or ma y cause 
increased risk to the participant. 
Enrollment 
Plan: Enrollment for adults on this trial will not begin until all patients on the AML monotherapy Dose Cohort 1 
clear the DLT window in the Fate sponsored Protocol FT538-101: FT538 as Monothe rapy and in 
Combination with mAbs in Advanced Hematologic Malignancies. 
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 11 of 79 MT2020-33 Enrollment of pediatric patients 12 years and older will not begin  until a minimum of 6 adults are 
treated on this study and/or the combination arm on FT538-[ADDRESS_1176707] likely include 17 patients or it could be as high as  25 patients if DLTs are encountered 
early. With 10-12 patients enrolled per year, accrual is expected to be completed wi thin 1.5 to 2 years. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 12 of 79 MT2020-33 Study Schema (Amended 03/01/2023)1 
There is no Day 0 in this treatment plan . 
 
                                                            DLT Assessment Period through Day 29                                                                       
                                                                                                                                                                       
                                                                                                                                                              assess         end            end  
                                              D   CY    CY         FT538             FT538            FT538            response   of DLT      of SR       Follow-up (months from  Day 1)  
                    
                    
Study Day                       -6    -5    -4   -3   -2         1          3         8        10         15                 22           29         42        3 mon  6 mon  9 mon  12 mon*      
No Day 0 
 
D:  DARZALEX FASPRO (1,800 mg daratumumab and 30,000 units hyaluronidas e) administered subcutaneously (subQ) once on Day 
-5  
 
FLU: fludarabine (FLU) 25 mg/m2 administered by [CONTACT_328926] 5 consecutive days, Day -6, Day -5, Day -4, Day -3, and day -2.  
 
CY: Cyclophosphamide 60 mg/kg  administered by [CONTACT_846365] r 2 consecutive days, Day -4 and Day -3   
 
FT538 : administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15  
 
All patients are monitored for dose limiting toxicities (DLTs) and  unacceptable toxicity using early stoppi[INVESTIGATOR_004] (SRs)  
Day 29 end of dose limiting toxicity (DLT) assessment (DLTs are defined on the next page and in Section 6.3.1  of the protocol) 
Day 42 end monitoring for excessive toxicity (SR events are defined on  the next page and in Section 6.3.2  of the protocol) 
 
*after the 12 month visit, follow-up transfers to the long-term follo w-up (LTFU) study  
 
Up to 5 dose levels of FT538 will be tested (including, a DL -1, only  used in event of DLT at DL 1):  
 
Dose Level (DL) Cohort FT538 cells/dose 
-1 5 x 107  
1 (start) 1 × 108  
2 3 × 108  
3 1 × 109  
4 1.5 × 109  
Each DL Cohort is separated by a minimum of 28 days (end of th e DLT period). A minimum of [ADDRESS_1176708] and the 2nd patient in 3 patient cohorts.  
 
 
1 Subjects enrolled prior to 16-Nov-2022 received Cy-Flu lymphodeple tion on day -4 and day -3 only; subjects enrolled prior to 20 -Mar-
2023 received 5 doses of daratumumab on day -12, -5, day +3 a nd day +17. See Appendix V for previous versions of schema.  FLU 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 14 of 79 MT2020-33 1 Objectives 
1.1 Primary Objective 
The primary objective of this study is to determine the maximum tolerated d ose 
(MTD) of FT538 when given in combination with daratumumab in the treatment o f 
acute myeloid leukemia. 
1.2 Secondary Objectives 
• To obtain preliminary estimates of efficacy as measured by [CONTACT_846366] (CR + CRi) assessed by [CONTACT_2006] 28, the primary trial endpoint based on 
the 2017 European LeukemiaNet (ELN) response criteria ( Döhner 2017 ) 
• Determine the overall response rate (ORR) at 1 year of follow-up 
• Determine progression free survival (PFS) and overall survival (OS) at 1 year 
of follow up 
• Determine safety of this combination as outlined by [CONTACT_410783] 
(AEs) measured by [CONTACT_3989] v5.0 
1.3 Correlative Objectives 
Correlative/exploratory objective include: 
• Change in level of expression of CD38 on leukemic blasts and normal tissue 
over time as determined by [CONTACT_398]38 measurement by [CONTACT_846367] 
• Determination of the PK of FT538 in the peripheral blood and marrow 
• Clinicopathological correlates of efficacy (level of CD38 expression, 
cytogenetics and molecular classification of the disease) 
• Clinicopathological correlates of safety (level of CD38 expression, cytogenetics 
and molecular classification of the disease) 
• Characterization of the kinetics of changes in CD38-expressing host immune 
cell populations including NK, Treg and MDSCs after exposure to 
daratumumab 
2 Background and Significance 
2.1 Introduction and Disease Under Treatment  
Treatment of relapsed and refractory acute myeloid leukemia (AML) remains an 
unmet need given that most patients are diagnosed at an advanced  age and have 
significant comorbidities. Strategies other than cytotoxic chemotherapy are 
desperately needed. CD38 is an ADP ribosyl cyclase membrane glycoprotein that 
is expressed in the majority of lymphocytes and on early myeloid precursors. 
(Drach 1994 ) Its presence has been has been variably reported on AML blasts. 
(Dos Santos 2014 ) We examined 51 bone marrow aspi[INVESTIGATOR_846338] #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 15 of 79 MT2020-33 absence of CD38 by [CONTACT_2085]-grade multicolor flow cytometry and found 39/51 
(76%) to have some level of expression of CD38 on AML blasts.(unpublished  data) 
Ligation and activation of CD38 has been linked to increased superoxide 
generation and increase in colony forming units of cell line.( Malavasi 2008 ) 
Inhibition of CD38 with DARA has been shown to decrease leukemia cell growth 
by [CONTACT_846368]. ( Mistry 2019 ) 
The expression of CD38 has also been shown to increase after exposure to ATRA  
through induction of differentiation through the RARa receptor. ( Drach 1994 , 
Buteyn 2018 ) Targeting AML cells using CD38 has been attempted using DARA 
in vitro . NSG cells were transplanted with T-cell depleted AML and treated with 
DARA or controls. The treated mice showed a reduction in tumor burden in th e 
spleen and peripheral blood but not bone marrow aspi[INVESTIGATOR_4026]. ( Dos Santos 2014 )  
This provides a rationale for targeted CD38 in AML. 
2.2 Natural Killer Cells 
Cancer immunotherapy is a rapi[INVESTIGATOR_846339], including advanced hematologic maligna ncies. 
Key advancements in this field include the development of mAbs that block  key 
inhibitory pathways on T cells, such as those that block programmed cell dea th 
receptor-1 (PD-1) and programmed cell death ligand-1 (PD-L1), and the  
development of adoptive transfer of immune cells as exemplified by [CONTACT_846369] c 
antigen receptor (CAR) T-cell therapy. Both approaches have led to the 
development of novel therapeutic regimens that have increased survival in p atients 
with a variety of solid and hematopoietic tumors. However, despi[INVESTIGATOR_846340], the majority of patients will either not respond or eventually experien ce 
disease relapse. Further understanding of the biology that enables these cell s to 
enter tumors and retain anti-tumor cytotoxic activity is important in order to 
maximize their clinical benefit for patients. 
NK cells are so named for their “natural” ability to kill cancer cells without prior 
sensitization ( Kiessling 1975 ). NK cells target and kill cancer cells by [CONTACT_15999] ( Figure 3 ), including direct cytotoxicity, cytokine secretion, and 
ADCC, which support their clinical investigation in oncologic indications as 
monotherapy and in combination with mAb therapy as follows: 
• Direct cytotoxicity through the targeted release of perforins and granzymes. 
Importantly, while major histocompatibility complex class I (MHC-I)-deficient 
cells evade CD8 T-cell recognition, they are preferential targets for NK cells 
and are highly susceptible to NK-cell-mediated killing ( Malmberg 2017 ). 
• Secretion of cytokines, including interferon-gamma (IFN γ) and tumor necrosis 
factor-alpha (TNF α), promote direct tumor-cell killing ( Wang R 2012 ). 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 16 of 79 MT2020-33 • ADCC, which occurs when an antibody binds to a tumor cell and the antibod y’s 
Fc region binds to the CD16 receptor on NK cells, triggering a targeted and 
engaged cytotoxic response toward the tumor cell ( Waldhauer 2008 ; Wang W 
2015 ). 
In addition to direct effects on tumor cells, NK cells can interact with th e adaptive 
immune system to generate and maintain adaptive immune responses against  
cancer cells as follows: 
• Killing of tumor cells by [CONTACT_846370] f or 
recognition by [CONTACT_217935] ( Dahlberg 2015 ).  
• Upon activation, NK cells secrete cytokines that recruit and activate 
endogenous T cells. Importantly, activated NK cells are potent producers of 
chemokines such as CXCL10, CCL4, and CCL5, which are known recruitment 
factors for T cells. Cytokines secreted by [CONTACT_846371], which serve as antigen-presenting cells to mediate adaptive 
immune responses ( Smyth 2002 ). 
Through these aforementioned mechanisms, NK cells have the intrinsic potential  
to bridge the innate and adaptive immune response and turn a tumo r that is 
immunologically “cold” to one  that is “hot,” characterized by [CONTACT_846372]. 
In clinical investigations, allogeneic NK-cell therapi[INVESTIGATOR_846341]-tumor activity. More than [ADDRESS_1176709] received allogeneic NK cells ( Veluchamy 2017 ). Notably, and 
unlike allogeneic T-cell therapi[INVESTIGATOR_014], allogeneic NK cells have not been associa ted 
with graft-vs-host disease (GvHD). Furthermore, with the exception of NK cells 
combined with a potent IL-[ADDRESS_1176710] ( Cooley 2019 ), allogeneic NK-cell therapi[INVESTIGATOR_846342] (CRS) or neurotoxicity, 
which are common complications observed with CAR T-cell therapi[INVESTIGATOR_014]. Complete 
remission rates ranging from 21% to 53% have been observed following a single 
administration of allogeneic NK cells in subjects with relapsed/refractory (r/r) AML 
(Miller 2005 ; Bachanova 2014 ; Romee 2016 ), and in subjects with poor prognosis 
refractory non-Hodgkin lymphoma ( Bachanova 2018 ). Clinical responses have 
also been reported in subjects with solid tumors, including non-small cell lu ng 
cancer ( Iliopoulou 2010 ; Tonn 2013 ), as well as in subjects with platinum-resistant 
ovarian cancer ( Geller 2011 ), melanoma ( Arai 2008 ), and renal cell carcinoma 
(Arai 2008 ). 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 17 of 79 MT2020-33 2.3 FT538 
FT538 is an allogeneic natural killer (NK)-cell immunotherapy produced from a 
clonal master human-induced pluripotent stem cell (iPSC) line with the following 
engineered elements: a) deletion of the gene encoding CD38 (i.e., C D38 knockout 
[KO]; Bjordahl 2019 ; Cichocki 2019 ); b) high-affinity, non-cleavable CD16 receptor 
(hnCD16; Jing 2015 ; Zhu 2020 ); and c) interleukin (IL)-15/IL-15 receptor alpha 
fusion protein (IL-15RF; Rubinstein 2006 ; Stoklasek 2006 ). The clonal master cell 
bank (MCB) used for the production of FT538 was generated by [CONTACT_134197] a single well-characterized iPSC clone in which a single 
IL15RF/hnCD16 expression cassette was inserted into the CD38 gene locus 
through non-viral-mediated targeted transgene integration. The use of  a clonal 
MCB as the starting material for routine current Good Manufacturing Practices 
(cGMP) production of FT538 is intended to directly address many of the limitation s 
associated with patient- and donor-specific cell therapi[INVESTIGATOR_014]. Notably, many doses of 
FT538 drug product can be uniformly produced in a single manufacturing 
campaign. These doses of drug product are homogeneous and are: (i ) tested to 
assure compliance with a pre-defined quality specification, (ii) cryopreserved in an  
infusion medium, and (iii) stored to maintain a sustainable inventory. As such,  
FT538 in the clinical setting has off-the-shelf availability for use in multi-dose 
regimens, which may prove critical for driving long-term durable responses in 
patients with progressing disease. 
The engineered features of FT538 are designed to result in increased activity 
against target tumor cells as monotherapy and when combined with monocl onal 
antibodies (mAbs) that can mediate antibody-dependent cellular cytotoxicity 
(ADCC). Important functional attributes of FT538 include the following: 
• FT538 is expected to have superior effector function compared to patients’ 
endogenous NK cells, which are typi[INVESTIGATOR_846343] (e.g., chemotherapy) and tumor suppressive 
mechanisms. FT538 mediates “innate  cytotoxicity” that is potent and specific 
to transformed cells. 
• The CD38 gene KO in FT538 is intended to prevent anti-CD38 antibody-
mediated NK-cell fratricide and consequently enhance ADCC when FT538 is 
administered with concurrent anti-CD38 mAb therapy ( Bjordahl 2019 ). In 
addition, NK cells with CD38 KO have been shown to be more resistant to 
oxidative stress and exhibit enhanced effector function ( Cichocki 2019 ). 
• FT538 expresses an hnCD16 Fc receptor. The high-affinity CD16 variant 
arising from a naturally occurring 158V polymorphism has demonstrated 
enhanced ADCC when combined with therapeutic mAbs in nonclinical studies. 
In clinical studies evaluating patients whose endogenous NK cells express the 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 18 of 79 MT2020-33 high-affinity CD16 Fc receptor variant, higher objective response rates and 
increased progression-free survival (PFS) were observed with treatment with 
rituximab, cetuximab, and trastuzumab ( Cartron 2002 ; Musolino 2008 ; Bibeau 
2009 ). In addition, hnCD16 contains the genetic alteration (S179P) that 
prevents cleavage of CD16 by [CONTACT_532848]17 ( Lajoie 2014 ; 
Jing 2015 ), a mechanism in the regulation and attenuation of NK-cell activity 
by [CONTACT_217944] ( Romee 2013 ). 
 
FT538 expresses IL-15RF, designed to provide an endogenous activation and 
proliferation signal, reducing the dependence on exogenous cytokine 
administration such as IL-[ADDRESS_1176711] been associate d with 
significant toxicities that may limit clinical usage when incorporated into clinical 
studies of peripheral blood NK cells ( Cooley 2019 ). 
 
These features justify investigation of FT538 in a broad array of oncology 
indications including, but not limited to, the following:  
• As monotherapy, e.g., acute myelogenous leukemia (AML), where FT538 may 
provide greater clinical benefit than current allogeneic NK-cell-based 
therapi[INVESTIGATOR_014]. 
• In combination with approved and investigational tumor-targeting, ADCC-
capable mAbs, including daratumumab, which target CD38, and are approved 
for the treatment of patients with multiple myeloma (MM). 
2.4 The Role of Daratumumab and Use of subQ DARZALEX FASPRO 
Daratumumab (DARA) is a monoclonal IgG1κ antibody against CD38, a 
transmembrane glycoprotein with both receptor and enzymatic functions 
expressed on hematopoietic cells. It was approved by [CONTACT_34033] [ADDRESS_1176712] apoptosis. 
A formulation of daratumumab for subcutaneous administration was developed to 
shorten the time required to administer daratumumab and to lessen the incidenc e 
and severity of infusion related reactions (IRRs) observed with intravenous (IV) 
daratumumab. A recombinant human hyaluronidase PH20 (rHuPH20) was used 
to decrease the injection volume required, facilitating the subcutaneous 
administration of daratumumab. FDA approval DARZALEX FASPRO was received 
in April [ADDRESS_1176713] of care drugs. ( DARZALEX FASPRO 
Prescribing Information ) 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 19 of 79 MT2020-33 In a pooled safety population of 490 patients who received DARZALEX FASPRO 
as monotherapy or in combination, 11% of patients experienced a syste mic 
administration-related reaction (Grade 2: 3.9%, Grade 3: 1.4%). Systemic 
administration-related reactions occurred in 10% of patients with the first injection, 
0.2% with the second injection, and cumulatively 0.8% with subsequent  injections. 
The median time to onset was 3.7 hours (range: 9 minutes to 3.5 days). Of the 8 4 
systemic administration-related reactions that occurred in 52 patients, 73 (87%) 
occurred on the day of DARZALEX FASPRO administration. Delayed systemic 
administration-related reactions have occurred in less than 1% of the patients. 
(DARZALEX FASPRO Prescribing Information ) 
2.[ADDRESS_1176714] proposed by [CONTACT_29630] (NCI) 
in the context of melanoma specific CTL by [CONTACT_134201]. (Dudley 
2002)  Lymphodepleting conditioning prior to adoptive transfer of lymphocytes is 
thought to promote persistence of adoptively transferred lymphocytes by [CONTACT_40397] 
"immunologic space” and providing a pool of homeostatic cytokines such as IL -15. 
The use of Cy/Flu-mediated lymphodepletion at the proposed doses and schedule 
is consistent with our previous human experience. ( Miller 2005 , Bachanova 2014 ) 
We and others ( Buteyn 2018 , Dos Santos 2014 , Drach 1994 ) have demonstrated 
that CD38 is present on hematopoietic cells. The expression on NK cells is in part 
the rationale for the CD38 knockout in the therapeutic product FT538. However, 
the proposed therapy plan may have an additional therapeutic advantage to target 
CD38 expressing regulatory T cells (Treg) and myeloid-derived suppression cells, 
depletion of which could enhance the anti-tumor activity of immunomodulato ry 
therapi[INVESTIGATOR_014]. Thus, the combination of FT538 and Daratumumab is expected to  have 
three therapeutic mechanisms of action in this protocol: 1) to target hos t immune 
suppressor cells and enhance NK cell adoptive transfer by [CONTACT_846373], 2) direct targeting of CD38 on AML cells and 3) providing the  
killing mechanism of natural cytotoxicity by [CONTACT_846374] (e.g. through dow n 
regulation of MHC class I and upregulates of stress ligands on AML; both 
increasing recognition and AML killing by [CONTACT_33152]). 
 
For the protocol amendment version dated 24 November 2022: Five patien ts have 
enrolled per Stage [ADDRESS_1176715] received FT538 with no related G3/[ADDRESS_1176716] increased the initial lymphodepletion 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176717] a more established regimen that has been previously described as 
effective with acceptable safety parameters [Miller et al. Blood. 2005]. 
 
Amendment March 202 3: In the original treatment plan we had hypothesized that 
multiple doses of daratumumab might allow lower doses of cyclophosphamide an d 
fludarabine (as used in enrollment to date) to prolong the pharmacokinetics of the 
FT538 NK cell product. However, new information on subjects treated to date 
shows that FT538 persistence in vivo was not achieved at [ADDRESS_1176718] cell doses, the biomarker goal of the treatment strategy. This was 
surprising because in our prior work, 14-day persistence was achieved in some 
subjects in various studies using high-dose cyclophosphamide and 5 days of 
fludarabine (HiCyFlu). In the November 2022 revision, we increased 
to HiCyFlu doses previously tested. With this plan, we will decrease to 1 dose of 
daratumumab as multiple doses are no longer needed to increase persisten ce. 
Given the long half-life of daratumumab (approximately 3 weeks), 1 dose is  
sufficient to mediate ADCC to CD38+ AML targets for the multi-dose FT538  
infusion plan while reducing the risk that study participants might develop toxicity 
requiring management with corticosteroids, which could also compromise FT538 
persistence. 
2.6 Study Rationale 
FT538 is an allogeneic natural killer (NK)-cell immunotherapy produced from a 
clonal master human-induced pluripotent stem cell (iPSC) line with the following 
engineered elements: a) deletion of the gene encoding CD38 (i.e., CD38 
knockout); b) high-affinity, non-cleavable CD16 receptor (hnCD16); and c) 
interleukin (IL)-15/IL-15 receptor alpha fusion protein (IL-15RF). 
 
The engineered features of FT538 are designed to result in increased activity 
against target tumor cells as monotherapy and when combined with mono clonal 
antibodies (mAbs) that can mediate antibody-dependent cellular cytotoxicity 
(ADCC). These features justify investigation of FT538 in advanced acute 
myelogenous leukemia (AML): 
• As monotherapy where FT538 may provide greater clinical benefit than curren t 
allogeneic NK-cell-based therapi[INVESTIGATOR_846344]538-101. 
• As proposed in this study use in combination with the tumor-targeting, ADCC -
capable mAb, daratumumab, which targets CD38. 
2.7 Rationale to Include Pediatric Patients 12 Years Old or Older 
Treatment of acute myeloid leukemia (AML) in children has improved rem arkably 
during the past decades; however, pediatric patients with relapsed and refracto ry 
AML still have poor outcomes ( Kaspers 2014 , Zwaan 2015 ). In fact, the probability 
of long -term survival in these patients is dismal at around 35%. These outcom es 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 21 of 79 MT2020-33 rely on disease-dependent characteristics which include cytogenetics, timing or 
relapse, and response to chemotherapy ( Pui 2011 ). Moreover, intensive 
chemotherapy and allogeneic hematopoietic cell transplantation (HCT) are 
required for a cure; this can lead to significant morbidity and mortality. Consideri ng 
poor outcome and high toxicity of current salvage therapi[INVESTIGATOR_014], new treatmen ts are 
needed.    
 
Daratumumab has been safely and effectively administered to children to treat 
autoimmune hemolytic anemia after HCT ( Schuetz 2018 ). Based on preclinical 
efficacy of daratumumab in acute leukemia ( Bride 2018 , Vogiatzi 2019 ) as well as 
case report of clinical efficacy of this agent in child with relapsed leukemia ( Ganzel 
2018 ), several clinical trials are now evaluating the safety and efficacy of 
daratumumab in children with relapsed or refractory leukemia.  
 
Given the dire prognosis of relapsed or refractory AML, and to ensure justice in 
this research protocol, we have included children ≥[ADDRESS_1176719] chosen to limit the age of enrolment to children ≥12 years such that 
assent can be obtained along with the consent of their parents/guardians.  
3 Study Design 
This Phase I open-label dose escalation study is conducted in two stages with a primary 
endpoint to identify the maximum tolerated dose (MTD) of FT538 when adm inistered with 
daratumumab in patients 12 years and older with advanced acute myeloid leuke mia 
(AML) and related myeloid diseases.  
FT538 is an off-the-shelf product comprised of allogeneic natural killer (NK)-cell 
immunotherapy lacking CD38 and expressing hnCD16 and IL-15RF. Daratumumab  is a 
targeted therapy (IgG1k human monoclonal antibody) that targets CD38. 
FT538 is administered once a week for 3 consecutive weeks (Day 1, Day 8, and Day 1 5). 
There is no Day 0 in this treatment plan. Up to 5 dose levels will be tested. Fixed  dose 
subcutaneous daratumumab is given on Day -5 prior to the FT538 cells as  
lymphodepletion. A short course of outpatient lymphodepleting chemotherapy is given 
from Day -6 through Day -3 to promote adoptive transfer. 
FT538 dose level cohorts are defined as:  
Table 1: Dose Level and Schedule 
Dose Level (DL) Treatment Plan for FT538 
-1 5 x 107 cells on Day 1, Day 8 and Day 15 
1 (start) 1 × 108 cells on Day 1, Day 8 and Day 15 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 22 of 79 MT2020-33 Dose Level (DL) Treatment Plan for FT538 
2 3 × 108 cells on Day 1, Day 8 and Day 15 
3 1 × 109 cells on Day 1, Day 8 and Day 15 
4 1.5 × 109 cells on Day 1, Day 8 and Day 15 
The trial is conducted with no intra-patient escalation.  
Enrollment on this trial will not begin until all patients on the AM L monotherapy Dose 
Cohort 1 clear the DLT window in the Fate sponsored Protocol FT538-101: FT538  as 
Monotherapy and in Combination with mAbs in Advanced Hematologic Maligna ncies. 
UMN is a participating site in this industry sponsored trial. 
Enrollment of pediatric patients (12 years and older) will not begin  until a minimum 
of 6 adults are treated on this study and/or the combination arm on FT538-[ADDRESS_1176720] and the 2nd patient in 3 patient cohorts. All patients are assessed 
for Dose Limiting Toxicity (DLT) as defined in the Schema and in Section 6.3.1. 
 
STAGE [ADDRESS_1176721]-track design (1 patient per dose cohort)  
Start at Dose Level 1 (DL1), enroll 1 patient per dose cohort separated by 28 days 
(DLT period) until the:  
• 1st pre-defined adverse event defined as any Grade 3 non-hematologic AE within 
72 hours of a FT538 infusion  
• and the patient completes the 28 day DLT period with no DLT- Activate Stage 1 
Step 2  
OR  
• 1st DLT event within [ADDRESS_1176722] dose of FT538 as defined in the Schema 
and in Section 6.3.1 - Activate Stage 2 (Stage 1 Step 2 is not used)  
OR 
• 10 patients are treated at the Dose Level 4 (This completes enrollment - Stage 1 
Step 2 and Stage 2 are not used) 
• If the first patient at dose level [ADDRESS_1176723] 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 23 of 79 MT2020-33 and the 2nd patient in 3 patient cohorts and a minimum of 28 days between dose 
cohorts. Continue dose escalation until: 
• 1st DLT event as defined in the Schema and Section 6.3.1 - Activate Stage 2  
OR  
• 10 patients are treated at the Dose Level 4  (This completes enrollment and Stage 2 
is not used.) 
• For Dose Level [ADDRESS_1176724]. If no 
DLT events within monitoring period, successive subjects may enroll without 
staggering.  
 
STAGE 2 Continual Reassessment Method (CRM) at the 1st DLT  
The study design changes to the CRM. Enrollment occurs in cohorts of three. A mini mum 
of [ADDRESS_1176725] patient in a cohort reaches Day 29 (end of DLT period). The MTD is ide ntified by 
[CONTACT_134186]: (1) the total Stage 2 maximum sample size of 25  is 
exhausted or (2) [ADDRESS_1176726] FT538 will be replaced.  
 
All patients are monitored for dose limiting toxicities (DLTs) and unaccepta ble toxicity 
using early stoppi[INVESTIGATOR_004].  
 
The definition of dose limiting toxicity (DLT) is found in Section 6.3.1 .  
 
The definition of excessive toxicity is found in Section 6.3.2 . 
 
Follow-up: Direct study participation ends at [ADDRESS_1176727] one dose of FT538:  After 
1 year, follow-up transfers to a separate long-term follow-up (LTFU) study to  continue the 
FDA’s recommended 15 year follow-up after treatment with a genetically modifie d cell 
therapy. Participation in the LTFU study is mandatory as part of the inclusion criteria o f 
this treatment study. 
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 24 of 79 MT2020-33 4 Patient Selection 
Study entry is open to persons 12 of age and older regardless of gender, race  or ethnic 
background. While there will be every effort to seek out and include females  and 
minority patients, the patient population is expected to be no different than th at of other 
advanced AML studies at this institution. Refer to Section 4.2.1  of FDA mandated delay 
in the enrollment of minor patients. 
4.1 Disease Specific Inclusion Criteria 
Acute myeloid leukemia relapsed/refractory after 2 lines of therapy; with CD38 
expression 
4.1.1 CD38 expression is defined by ≥20% of malignant cells with CD38 
expression by [CONTACT_846375] (within 30 
days of enrollment – archived or fresh) .  
4.1.2 Relapsed/refractory is defined as failure to achieve at least a Morphological 
Leukemia Free State (MLFS) or reverting from MLFS.  
4.1.3 Lines of therapy are defined as (must have had 2 prior therapi[INVESTIGATOR_014]): 
• One cycle of an Intensive induction chemotherapy such as 7+3, 5+2, 
MEC, FLAG, FLAG-Ida, or CLAG – small molecule inhibitor 
• Four weeks of HMA-based induction – small molecule inhibitor 
• Hematopoietic stem cell transplantation (HSCT), must be >[ADDRESS_1176728] 
• Gemtuzumab Ozogamicin 
• LDAC + glasdegib 
• Biomarker-specific targeted agents (FLT3 inhibitors, IDH1/2 inhibitors, 
others if available) 
• Other treatments could be considered after discussion with the PI 
4.2 Inclusion Criteria 
4.2.1 Age 12 years or older at the time of consent - Please note, enrollme nt of 
minors will be begin until permission to proceed is received from the FDA. 
At that time, the protocol will be updated to open enrollment to minors. 
4.2.2 Weight ≥ [ADDRESS_1176729] pre-dose 
packaging 
4.2.3 Karnofsky performance status of 70-100% for 16 years and older or La nsky 
Play Score of 70-100 for ≥1 2 and < 16 years of age (refer to Appendix I ) 
4.2.4 Evidence of adequate organ function within 14 days prior to starting stu dy 
treatment defined as: 
o Estimated Glomerular Filtration Rate (estimated creatinine clearance) 
≥50 mL/min/1.73m^2 
o Total bilirubin ≤ 5 × upper limit normal (ULN), not applicable for patients with 
Gilbert’s syndrome   
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176730] ≤3 × ULN and ALT ≤ 3 × ULN, not applicable if determined to be directly 
due to underlying malignancy 
4.2.5 Contraceptive use by [CONTACT_198654] 
o Female subjects: Women of childbearing potential (WOCBP) must use a 
highly effective form of contraception from the screening visit until at least 
12 months after the final dose of cyclophosphamide (CY), at least [ADDRESS_1176731]. 
o Male subjects: Males with a female partner of childbearing potential or a  
pregnant female partner must be sterile (biologically or surgically) or use a 
highly effective method of contraception from the screening visit until at 
least [ADDRESS_1176732].  
4.2.7 Patient ≥18 years provides voluntary written consent prior to the 
performance of any research related procedure. Minors (<18 years) 
provide voluntary written assent with the parent/guardian signing the 
treatment consent prior to the performance of any research related 
procedure. 
4.3 Exclusion Criteria  
4.3.1 Diagnosis of acute promyelocytic leukemia (APL)  
4.3.[ADDRESS_1176733] within 14 days prior to study 
treatment start 
4.3.3 Known allergy to any of study drugs or their components 
4.3.4 Clinically significant cardiovascular disease including any of the following: 
myocardial infarction within [ADDRESS_1176734] study treatment; unstable 
angina or congestive heart failure of [LOCATION_001] Heart Association Grade 2 
or higher ( Appendix II ) or cardiac ejection fraction <40%  
4.3.5 Any known condition that requires systemic immunosuppressive therapy 
(> 5mg prednisone daily or equivalent) during the FT538 dosing period ([ADDRESS_1176735] dose) excluding 
pre-medications – inhaled and topi[INVESTIGATOR_12977] 
4.3.6 Receipt of any biological therapy, chemotherapy, or radiation therapy, 
except for palliative purposes, within 2 weeks prior to Day 1 or five half-
lives, whichever is shorter; or any investigational therapy within [ADDRESS_1176736] dose of daratumumab.  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 26 of 79 MT2020-33 4.3.7 Known active central nervous system (CNS) involvement or treated CNS 
disease that has not cleared. If prior disease related CNS involvement 
must have completed effective treatment of their CNS disease at least 2 
months prior to Day 1 with no clinical evidence of disease  
4.3.8 Non-malignant CNS disease such as epi[INVESTIGATOR_002], CNS vasculitis, or 
neurodegenerative disease or receipt of medications for these conditions 
in the 2-year period leading up to study enrollment   
4.3.9 Clinically significant untreated/uncontrolled infection 
4.3.10 Live vaccine <[ADDRESS_1176737]-disease (GvHD) requiring systemic immune-
suppression within [ADDRESS_1176738] or may cause increased risk to the participant. 
5 Patient Screening and Enrollment 
5.1 Registration with the Masonic Cancer Center Clinical Trials Office 
Any patient who is consented is to be entered in OnCore by [CONTACT_846376] y 
Coordinator or designee.  
 
If a patient is consented but is not enrolled in the study treatment (i.e. is fo und to 
be ineligible based on pre-transplant inclusion/exclusion criteria) , the patient’s 
record is updated in OnCore as a screen failure and reason for exclusion recor ded.  
5.[ADDRESS_1176739] based on an eligibility assessment documented in the patient’s medica l 
record. The patient is placed in the currently enrolling dose cohort. 
5.3 Patients Who Do Not Begin Study Treatment 
If a patient is enrolled in the study (i.e. assigned a sequence numb er) and is later 
found unable to begin FT538, the patient will be removed from study and treated 
at the physician’s discretion . The study staff will update OnCore of the patient’s 
non-treatment status (off study) with the reason for removal from study prior to 
starting study treatment clearly indicated. The patient will be replaced to complete 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176740] continue follow-up per Section 8 . 
 
6 Treatment  Plan  
In order to provide optimal patient care and to account for individual medical 
conditions, investigator discretion may be used in the prescribing of all supportive  care 
drug therapy (i.e. acetaminophen, diphenhydramine, antimicrobials, etc.) . In this 
study, hydroxyurea may be used at any time to control peripheral blood blasts. 
 
Because they may inhibit NK cell function, additional systemic corticosteroids shou ld 
be avoided unless absolutely required. Standard pre-medications for study drug s 
(including corticosteroids as daratumumab pre-meds) are permitted.   
 
There is some flexibility in the timing of the treatment as long as the orderi ng of the 
treatment is maintained and a minimum of [ADDRESS_1176741] FT538 infusion. The below Table 1 represents the treat ment 
plan when Day 1 is a Monday and treatment is given as planned. 
 
Table 1. Treatment Plan Example with Day 1 = Monday 
Study Day Day of Week Agent Protocol Section 
Day – 6 Tuesday FLU Section 6.2  
Day -5 Wednesday Daratumumab, FLU Section 6.1, Section 6.2  
Day -4, Day -3 Thursday, Friday CY/FLU Section 6.2  
Day -2 Saturday FLU Section 6.2  
Day 1 Monday FT538 Section 6.3  
Day 8 Monday FT538 Section 6.3  
Day 15 Monday FT538 Section 6.3  
 
There is no Day 0 in this treatment plan. 
6.1 Daratumumab Administration Guidelines 
Daratumumab subQ 1800 mg co-formulated with 30,000 units of hyaluroni dase 
(rHuPH20) into the subcutaneous tissue of the abdomen approximately 3 inches 
[7.5 cm] to the right or left of the navel over approximately 3-[ADDRESS_1176742] FT538 infusion. 
 
• Never inject DARZALEX FASPRO into areas where the skin is red, bruised, 
tender, hard, or areas where there are scars. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 28 of 79 MT2020-33 • Pause or slow down delivery rate if the patient experiences pain. In the  event 
pain is not alleviated by [CONTACT_846377], a second 
injection site may be chosen on the opposite side of the abdomen to  deliver the 
remainder of the dose. 
• During treatment with DARZALEX FASPRO, do not administer other 
medications for subcutaneous use at the same site as DARZALEX FASPRO. 
 
Pre- and Post-Medications: 
Administer the following pre-medications 1-3 hours before daratumumab: 
• Acetaminophen 650 to 1,000 mg orally 
• Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously 
• Methylprednisolone 60 mg (or equivalent) orally or intravenously. Dose Day -5 
and Day -4. 
 
Refer to Section 2.4  for injection related reaction presented in the current 
Investigator Brochure. With the subcutaneous route, in a pooled safety populat ion 
of 490 patients who received DARZALEX FASPRO as monotherapy or in 
combination, 11% of patients experienced a systemic administration-related 
reaction (Grade 2: 3.9%, Grade 3: 1.4%). Systemic administration-related 
reactions occurred in 10% of patients with the first injection, 0.2% with the second  
injection, and cumulatively 0.8% with subsequent injections.   
 
For patients with a history of chronic obstructive pulmonary disease, consider 
prescribing short and long-acting bronchodilators and inhaled corticosteroids. F 
 
Prophylaxis for Herpes Zoster Reactivation: 
Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week 
after starting DARZALEX FASPRO and continue for 3 months following  the end of 
treatment.  
 
Monitoring: 
Monitor patients for systemic administration-related reactions and localized 
injection site reaction.  
 
A recommended post-injection observation is 3.[ADDRESS_1176743] injection per institutional standards. 
 
For anaphylactic reaction or life-threatening (Grade 4) administration-related 
reactions, immediately and permanently discontinue DARZALEX FASPRO. 
Consider administering corticosteroids and other medications after the 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 29 of 79 MT2020-33 administration of DARZALEX FASPRO depending on dosing regimen and me dical 
history to minimize the risk of delayed (defined as occurring the day after 
administration) systemic administration-related reactions. 
 
Subcutaneous administration of daratumumab may be associated with a local 
injection site reactions, such as induration and erythema. The reactions usuall y 
resolved within 60 minutes. Local injection site reactions should be managed per 
institutional standards. 
 
DARZALEX FASPRO dose reductions are not recommended. Skipped or delaye d 
dosing is permitted. 
6.2 Cyclophosphamide/Fludarabine Lymphodepletion Guidelines 
A lymphodepleting regimen of fludarabine and cyclophosphamide is given in the 
outpatient clinic on 5 consecutive days (Day -6, Day -5, Day -4, Day -3 and Day -
2). 
 
The administration of the preparative regimen will follow the institutional dosing 
guidelines. Dose and/or schedule adjustments consistent with the standard of care 
may be made on an individual patient basis as needed for safety.  
 
Fludarabine 25 mg/m2 is administered as a 1 hour intravenous (IV) infusion per 
institutional guidelines once a day on 5 consecutive days (Day -6, Day -5, Day -4, 
Day -3 and Day -2). 
 
Cyclophosphamide 60 mg/kg is administered as a 2 hour intravenous infusion per 
institutional guidelines once a day on Day -4 and Day -3. 
  
Cyclophosphamide dosing is calculated based on ABW (Actual Body Weight) 
unless ABW is >150% of the IBW (Ideal Body Weight). 
Adjusted body weight = IBW + 0.5(ABW-IBW). 
 
Cyclophosphamide associated hydration will be given according to recommend ed 
institutional standards. 
6.3 FT538 Administration 
FT583 is given in the same manner for all patients treated on this study. Refe r to 
Section 3  for the study design/enrollment plan. 
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 30 of 79 MT2020-33 FT538 will be provided by [CONTACT_846378] (MCT) Laboratory until needed. 
FT538 is thawed on the unit prior to administration. 
 
FT538 is administered as an IV infusion via gravity using an IV administration set 
with an in-line filter at the patient’s assigned dose levels on Day 1, Day 8, and 
Day 15. Refer to Table 2 below. 
 
Table 2: FT538 cell product dose levels (bag requirements)  
Dose Level FT538 cells 
-1 5 × 107 FT538 cells/dose (1 bag at 5 × 107 cells/bag) 
1 (start) 1 × 108 FT538 cells/dose (1 bag at 1 × 108 FT538 cells/bag) 
2 3 × 108 FT538 cells/dose (3 bags at 1 × 108 FT538 cells/bag) 
3 1 × 109 FT538 cells/dose (2 bags at 5.0 × 108 FT538 cells/bag) 
4 1.5 × 109 FT538 cells/dose (3 bags at 5.0 × 108 FT538 cells/bag) 
Dosing is based on hnCD16 expression, where 90%–10% of FT538 cells express hnCD16. 
 
FT538 Thawing Overview:  FT538 is provided in one or more cryopreserved bags 
based on the patient’s dose level. The correct number of bags are transferred to 
the site of infusion using a validated cooler. Thawing occurs on the unit just prior 
to administration. When dose level requires multiple bags, bags are thawed 
sequentially. FT538 is stable for up to [ADDRESS_1176744] begin within 60 minutes of thawing.  
FT538 Infusion guidelines:  FT538 must be administered via gravity using a Fate 
approved IV administration set with an in-line filter. Total infusion time per  bag is 
less than [ADDRESS_1176745] thawing. To infusion 3 bags of cells (the maximum 
required for the dose levels in this study), total infusion time from the start o f the 
1st bag to the end of the last bag would be 30-[ADDRESS_1176746] th e 
empty study drug bag/tubing in accordance with local site policy. 
 
Pre-Medications : Prior to administration of FT538 and 4-6 hours later, patients 
should receive acetaminophen 650 mg orally (PO) and diphenhydramine 25 PO.  
Corticosteroids should not be used as pre-medication for FT538. 
Vital Signs: Vital signs (temperature, systolic and diastolic blood pressure, heart 
rate, and respi[INVESTIGATOR_1487]) are performed in association with the FT538 infusion a t 
the following time points: within 15 minutes of the infusion start, at 10 (–5) minu tes 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 31 of 79 MT2020-33 during infusion, and every 15 (–5) minutes for 1 hour after the end of the las t 
administered bag of FT538. 
 
Collection of research sample 30 (–5) minutes after the last bag of FT538 is 
infused per Section 8.2 . One or more bags are given depending on the dose level. 
 
Monitoring for Infusion Related Reactions: All patients are monitored for signs 
of an infusion related reaction. The highest grade infusion reaction for the FT [ADDRESS_1176747] be documented (and if applicable reported as a dose limiting toxicity  
and/or an SAE). 
 
Refer to Section 7.1  for the management of any grade of an infusion related 
reaction. 
 
If a Grade 3 or 4 infusion related reaction occurs (defined as CTCAE v 5.0 – 
prolonged or life-threatening consequences), the infusion is stopped if po ssible 
(i.e. no additional bags of cells are given) and the patient receives sup portive care 
per Section 7.1  guidelines. The patient will receive no further FT538.  
 
All patients are monitored for adverse events, dose limiting toxicity, stoppi[INVESTIGATOR_846345], and death per Section 10 . 
 
Refer to Section 7  for management of FT538 related toxicity. 
6.3.1 Dose Limiting Toxicity 
Dose limiting toxicity (DLT) is defined as any AE (based on CTCAE v5) that is at 
least possibly related to FT538 and not related to disease progression that occurs 
after the first FT538 infusion through the end of the DLT assessment period  on 
Day 29 as defined below: 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 32 of 79 MT2020-33 Table 3: Definition of Dose Limiting Toxicity  
Dose Limiting Toxicity (DLT)  Exceptions 
• Any Grade 4 non-hematologic AE  • Fever associated with CRS that occurs in 
the context of Grade <3 CRS 
• Grade 3 pulmonary or cardiac AE of 
any duration 
• Grade 3 immune cell associated 
neurotoxicity syndrome (ICANS) of any 
duration 
• Any other Grade 3 non-hematologic AE 
of >72 hours duration* • Grade 3 renal or hepatic AE lasting < 7 
days 
• Grade 3 fatigue lasting ≤ 3 days  
• Grade 3 laboratory abnormality, unless 
otherwise specified that is asymptomatic 
and not clinically significant 
• Grade ≥2 acute GvHD requiring 
systemic steroid administration  
* Note: Febrile neutropenia is not a hematologic AE or laboratory  abnormality  
6.3.[ADDRESS_1176748] will be monitored for unaccepta ble 
toxicity using early study stoppi[INVESTIGATOR_004] (SR). The following events are considered 
excessive toxicity per Section 12.4.  
• Excessive treatment emergent adverse events that meet DLT criteria within the 
DLT period - The trial will be stopped if the posterior probability that the lowest 
dose is unacceptably toxic (> 25% of patients) is greater than 80%; 
• Grade 4 or greater FT538 infusion related reaction; 
• Aplasia at Day 42 (ANC <500) after at least 1 week of growth factor (i.e. G-CSF)  
with an aplastic bone marrow in the absence of leukemia (<5% cellularity); 
• Any death within [ADDRESS_1176749] dose of FT538 and not attribu table to 
disease progression.  
6.4 Permitted and Prohibited Concomitant Medications/Therapi[INVESTIGATOR_846346], investigator discretion may be used in the prescribing of all supportive 
care drug therapy (i.e. acetaminophen, diphenhydramine, antimicrobials, etc.). 
Growth factor should be avoided until [ADDRESS_1176750] dose of FT538 unless  
medically indicated. If at Day 29, bone marrow recovery is delayed, growth factor 
(i.e. G-CSF) should be initiated. Aplasia at Day [ADDRESS_1176751] 1 week of GF is 
considered excessive toxicity as detailed in Section 6.3.2 . 
 
At the treating investigator’s discretion, hydroxyurea may be used at any time to 
control peripheral blood blasts and/or white blood count. Although classified as a  
chemotherapy, in this situation it is considered suppressive only and part of 
supportive care as it has no impact on actual disease blasts.  Consequently, t he 
use of hydroxyurea would not affect a patient’s evaluability for response and 
toxicity. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176752] of the patient. 
 
An End of Treatment (EOT) assessment occurs at Day 29 to confirm no ong oing 
side effects/toxicity related to study treatment. If ongoing toxicity, it should be 
managed as medically appropriate and documented, it if meets the cri teria for 
documenting as an AE be followed until resolution or stabilization.  
Patients are monitored for unacceptable toxicity using early study stoppi[INVESTIGATOR_004] 
(SR) through Day 42. 
 
Any patient receiving at least one dose of FT538 is followed per Section 8.1 and 
on the Long-Term Follow-Up protocol per Section 6.7 . 
6.6 Follow-Up for Disease Response and Survival (Duration of Study 
Participation) 
Patients are followed for disease response until disease progression/relapse and 
then survival until the end of the 12 month follow-up period (from the 1st dose of 
FT538). 
 
Follow-up assessments may be in person, by [CONTACT_61706], or local 
medical doctor if patient is no longer seen at the treating institution. In p erson 
follow-up visits solely for this research study are not required and may be linked 
with a standard of care visit. Refer to Section 8  for allowable time related windows 
around each follow-up time points. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 34 of 79 MT2020-33  
Follow-up may end early if any of the following apply: 
• consent is withdrawn  
• patient did not receive FT538 – if a patient is not evaluable, follow only until the 
resolution or stabilization of treatment related toxicity 
• new anti-cancer treatment is started (follow for survival only) 
• patient is discharged to hospi[INVESTIGATOR_6125] (terminal) care    
 
If a person ends follow-up before the 12 months study period (i.e. withdraws 
consent, lost to follow-up), public records will be searched for survival information  
for the survival endpoint. 
 
Any patient receiving at least [ADDRESS_1176753] and the long-term  safety 
risk is not known and may include conditions with delayed onset relative to FT538 
administration. Specific conditions potentially related to engineered cellular 
immunotherapy products such as FT538, including but not limited to, new 
malignancies, new or worsening neurologic disorders, new or worsening 
autoimmune or rheumatologic disorder, or new hematologic disorder will be 
documented and reported to the FDA as part of IND the annual report. 
 
This LTFU reporting requirement is fulfilled through a separate study. Consent to 
the LTFU study is obtained at the time of consent for the treatment study and a 
condition for eligibility to receive treatment. If a patient does not receive FT538, 
follow-up on the LTFU study is not relevant. Refer to the LTFU protocol for 
withdrawal procedures.  
 
7 Recommended Management Guidelines for Specific Adverse 
Events Associated with FT538 
Refer to Section 6.1  for management of daratumumab injection related reactions 
and Section 9.2.7  for potential risks. 
 
Refer to Appendix III  for potential toxicities for the cyclophosphamide and 
fludarabine. 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 35 of 79 MT2020-33 No FT538 clinical data are available. For this reason: 
1) Enrollment of adult patients on this trial will not begin until all p atients on the AML 
monotherapy Dose Cohort 1 clear the DLT window in the Fate sponsored 
Protocol FT538-101: FT538 as Monotherapy and in Combination with mAbs in 
Advanced Hematologic Malignancies. UMN is a participating site in the industry 
sponsored trial. 
2) Enrollment of pediatric patients (12 years through 17 years) will not begin u ntil a 
minimum of 6 adults are treated on this study and/or the combination arm o n 
FT538-101 and safety data is submitted to the FDA for their review an d 
permission to proceed with the enrollment of children is received. 
The long-term safety risk is not known and may include conditions with delayed 
onset relative to FT538 administration. 
 
Suggested guidelines for the management of specific AEs are outlined below. 
 
 
Dose and schedule modifications of FT538 for AEs are as follows: 
• If a Grade 3 or Grade 4 DLT is observed, then the subsequent FT538 infusions 
could be omitted. 
• If a Grade [ADDRESS_1176754] one lower dose level. 
o Dose reduction will not be required for Grade 3 laboratory abnormalities tha t are 
not clinically significant 
• If a Grade [ADDRESS_1176755] FT538 infusion: 
− If recovery to baseline is not observed by [CONTACT_2006] 8, the scheduled Day 8 FT538 
infusion could be skipped. 
− If recovery to baseline is observed by [CONTACT_2006] 15, the scheduled Day 15 FT538 
infusion may be administered. 
− If recovery to baseline is not observed by [CONTACT_2006] 15, the scheduled Day 15 
FT538 infusion will be skipped. 
o For AEs occurring after the second FT538 infusion, if recovery to baseline is not  
observed by [CONTACT_2006] 15, the scheduled FT538 infusion will be skipped. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 36 of 79 MT2020-33 • If a Grade 3 hematologic AE that is not a DLT is observed, then FT538 dosing will 
continue according to schedule and without dose modification. 
Additional modifications to the FT538 dosing schedule, including dosing delays, 
will be based on consultation between the investigator and the principle  
investigator. (Note: Given the extremely high incidence of febrile neutropenia is 
patients with relapsed/refractory AML, febrile neutropenia will not be recorded as 
a hematologic AE; grade 3 febrile neutropenia falls into the same category as “Any 
other Grade 3 non- hematologic AE” pe r the table in section 6.3.1)  
 
All adverse events will be defined and graded using the Common Term inology 
Criteria for Adverse Events (CTCAE) Version 5.0 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_
v5_Quick_Reference_5x7.pdf 
7.1 Infusion Related Reaction Associated with FT538 
Patients will be observed for the occurrence of acute allergic/anaphylactoid 
infusion reactions such as rigors and chills, rash, urticaria, hypotension, dyspnea, 
and angioedema during and after the infusion.  
 
The management of acute infusion or allergic reactions that occur during FT538  
administration is described below. 
If Grade 4 Infusion-Related Reaction (Life-threatening consequences; urgent 
intervention indicated):  
Stop FT538 administration. Do not restart. 
The volume of FT538 administered prior to the infusion-related reaction must be 
documented; retain any remaining product and contact [INVESTIGATOR_124]. Maakaron or designee 
for further instructions.  
If Grade ≤3 Infusion-Related Reaction (e.g., not rapi[INVESTIGATOR_86025]/or brief interruption of infusion); recurren ce of 
symptoms following initial improvement; hospi[INVESTIGATOR_5176]): 
• Interrupt FT538 administration. 
• Manage symptoms, e.g., with antihistamines, antipyretics and analgesics, 
according to standard institutional practice standards. 
• Resume FT538 administration only upon complete resolution of the infusion-
related reaction and at the discretion of the Investigator. Given that FT538 
administration may involve single or multiple bags depending on the total 
planned dose and accounting for the stability of FT538 post-thaw, FT538 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 37 of 79 MT2020-33 administration may continue following resolution to a Grade 1 infusion-related  
reactions as follows: 
If single-bag FT538 dosing: 
• No additional FT538 may be administered. 
• The volume of FT538 administered prior to the infusion-related reaction must 
be documented; retain any remaining product and contact [CONTACT_1016] (or 
designee) for further instruction. 
• Additional bags may not be administered to make up for FT538 that was not 
administered from the bag during which the infusion-related reaction 
occurred. 
If multiple-bag FT538 dosing: 
• The volume of FT538 administered from the bag during which the infusion-
related reaction occurred must be documented; retain any remaining product 
from the bag and contact [CONTACT_134213]. 
• If dosing with additional FT538 bags was planned, they may be thawed and 
administered. 
• Additional bags beyond what was originally planned may not be 
administered to make up for FT538 that was not administered from the bag 
during which the infusion-related reaction occurred. 
7.[ADDRESS_1176756] tightness and wheezing, nausea and vomiting, and 
cardiovascular instability. Treat by [CONTACT_532852], medicating with 
antihistamines, and treating symptoms per institutional practice. It is 
recommended patients receive IV hydration with normal saline (NS) [ADDRESS_1176757] 
with reagents of animal origin, and FT538 has a final formulation which conta ins 
albumin (human). As with any product of human and/or animal origin, trans mission 
of infectious disease and/or disease agents by [CONTACT_846379]. FT538 has been extensively tested to minimize the potential risk of disease 
transmission. However, these measures do not completely eliminate the risk. F or 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176758] or prevent disease 
transmission ( AABB 2016 ).   
7.4 Cytokine Release Syndrome (CRS) or CRS-Like Symptoms 
While CRS is a clearly defined syndrome with T-cell therapy, it is generally no t 
believed to be a toxicity associated with NK cell therapi[INVESTIGATOR_532831]8+  T 
cells, e.g., exogenous IL-15 ( Cooley 2019 ).  
 
If CRS is suspected, CRP and ferritin levels should be assessed in the clinical 
laboratory, and a research related serum sample should be collected for an IL-6  
level (if feasible).  
 
CRS must be graded as outlined in the ASTCT CRS consensus grading system 
per Section 10 Table 10 (Lee 2019) . 
 
If CRS occurs (e.g. a differential diagnosis is recorded in the institutional medical 
record), CRP and ferritin levels should be done three times weekly until the 
resolution of CRS per Section 8.1 . In addition, a research related serum sample 
should be collected for an IL-6 level at the time of any change (i ncrease or 
decrease) in the CRS grade. Because patients may be outpatients any m issed 
collection time points will not be a protocol deviation. 
 
Management of CRS should follow the recommended management a lgorithm 
provided in Table 4 ( Neelapu 2018 ) and/or institutional practice. 
 
Table 4: Recommendations for the Management of Cytokine Release Syndrome  
Grade  Sign/Symptom  Management  
Grade 1 Fever or 
organ toxicity • Acetaminophen and hypothermia blanket for the treatment of fever 
• Ibuprofen can be used as second treatment option for fever, if not contraindicated 
• Assess for infection using blood and urine cultures, and chest radiography 
• Empi[INVESTIGATOR_132327] ‑spectrum antibiotics and filgrastim if neutropenic 
• Maintenance IV fluids for hydration 
• Symptomatic management of constitutional symptoms and organ toxicities 
• Consider tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV for persistent (lasting ≥3 
days) and refractory fever 
Grade 2 Hypotension • IV fluid bolus of 500 –1,000 mL of normal saline 
• Can give a second IV fluid bolus if systolic blood pressure remains <90 mmHg 
• Tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV for the treatment of hypotension 
that is refractory to fluid boluses; up to [ADDRESS_1176759] 8 hours. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 39 of 79 MT2020-33 Table 4: Recommendations for the Management of Cytokine Release Syndrome  
Grade  Sign/Symptom  Management  
• If hypotension persists after two fluid boluses and anti ‑IL‑6 therapy, start 
vasopressors, consider transfer to ICU, obtain echocardiogram, and initiate other 
methods of hemodynamic monitoring 
• In subjects at high-risk b or if hypotension persists after 1 –2 doses of anti ‑IL‑6 
therapy, dexamethasone can be used at 10 mg IV every 6 hours 
• Manage fever and constitutional symptoms as in Grade 1 
Hypoxia • Supplemental oxygen 
• Tocilizumab or siltuximab – corticosteroids and supportive care, as recommended for 
the management of hypotension 
Organ toxicity • Symptomatic management of organ toxicities, as per standard guidelines 
• Tocilizumab or siltuximab – corticosteroids and supportive care, as indicated for 
hypotension 
Grade 3 Hypotension • IV fluid boluses as needed, as recommended for the treatment of Grade 2 CRS 
• Tocilizumab and siltuximab as recommended for Grade 2 CRS, if not administered 
previously 
• Vasopressors as needed 
• Transfer to ICU, obtain echocardiogram, and perform hemodynamic monitoring as in 
the management of Grade 2 CRS 
• Dexamethasone 10 mg IV every 6 hours; if refractory, increase to 20 mg IV every 6 
hours 
• Manage fever and constitutional symptoms as indicated for Grade 1 CRS 
Hypoxia • Supplemental oxygen including high ‑flow oxygen delivery and non ‑invasive positive 
pressure ventilation 
• Tocilizumab or siltuximab plus corticosteroids and supportive care, as described 
above 
Organ toxicity • Symptomatic management of organ toxicities as per standard guidelines 
• Tocilizumab or siltuximab plus corticosteroids and supportive care, as described 
above 
Grade 4 Hypotension • IV fluids, anti ‑IL‑6 therapy, vasopressors, and hemodynamic monitoring as defined 
for the management of Grade 3 CRS 
• Methylprednisolone 1 g/day IV 
• Manage fever and constitutional symptoms as in Grade 1 CRS 
Hypoxia • Mechanical ventilation 
• Tocilizumab or siltuximab plus corticosteroids and supportive care, as described 
above 
Organ toxicity • Symptomatic management of organ toxicities as per standard guidelines 
• Tocilizumab or siltuximab plus corticosteroids and supportive care, as described 
above 
CRS, cytokine release syndrome; ICU, intensive care unit; IV, intravenou s.  
NOTE: All medication doses indicated are for adults.  
a Maximum amount of tocilizumab per dose is 800 mg.  
b High-risk subjects include those with bulky disease and those  with comorbidities. 
Source: Neelapu et al. 2018 ; Actemra USPI  
[INVESTIGATOR_846347] #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176760] guidelines for grading ICANS ( Table 10 ; Lee et al. 2019 ) based on the 
ICE score. 
While CNS toxicity is a clearly defined syndrome associated with T-cell-base d 
therapi[INVESTIGATOR_014], it is rare and generally not believed to be a toxicity associated wi th NK 
cell therapi[INVESTIGATOR_014]. Neurotoxicity was reported in one trial of adoptively transferred NK 
cells given with subcutaneous IL-15 but the mechanism of the toxicity was not we ll 
defined ( Cooley 2019 ). Nervous system toxicities following CD19 CAR-T therapy 
is characterized by [CONTACT_134217], confusion, delirium, aphasia, obtundatio n, 
and seizures ( Yescarta USPI 2017 ; Kymriah USPI 2018 ). Cases of cerebral edema 
have also been reported ( Brudno 2016 ). 
If signs and symptoms of CNS toxicity occurs, it will be graded as outlined in  the 
ASTCT consensus grading system for ICANS ( Lee 2019 , Section 10) ; management 
should follow current recommendations for CAR-T-cell therapi[INVESTIGATOR_014] ( Neelapu 2018 ). 
If the patient develops neurological toxicity for which cerebrospi[INVESTIGATOR_872] (CSF ) 
analysis is performed, in addition to standard clinical testing, the sample wi ll be 
tested for Human Herpes Virus (HHV 6&7) since HHV6 and HHV-[ADDRESS_1176761] guidelines for grading ICANS ( Section 10 ) based on the immune 
cell-associated encephalopathy (ICE) score. Determinants of the ICE score are 
outlined below. 
ICE Score Determination: 
• Orientation: Orientation to year, month, city, hospi[INVESTIGATOR_307]: 1 point each for 
maximum of 4 points 
• Naming: Name 3 objects (e.g., point to clock, pen, button): 1 point each for 
maximum of 3 points 
• Following commands: (e.g., show me 2 fingers or close your eyes and stick 
out your tongue): 1 point 
• Writing: Ability to write a standard sentence (e.g., our national bird is the bald 
eagle): 1 point 
• Attention: Count backwards from 100 by [CONTACT_134218]: 1 point 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 42 of 79 MT2020-33 Table 6:  Recommendations for the Management of Encephalopathy Syndrome  
Grade Management  
Grade 1 
 • Vigilant supportive care; aspi[INVESTIGATOR_134174]; IV hydration  
• Withhold oral intake of food, medicines, and fluids, and assess swallowing  
• Convert all oral medications and/or nutrition to IV if swallowing is impaired  
• Avoid medications that cause central nervous system depression  
• Low doses of lorazepam (0.25 –0.5 mg IV every 8 hours) or haloperidol (0.5 mg IV every 6 
hours) can be used, with careful monitoring, for agitated subjects  
• Neurology consultation  
• Fundoscopic exam to assess for papi[INVESTIGATOR_59411]  
• MRI of the brain with and without contrast; diagnostic lumbar puncture with measurement of 
opening pressure; MRI spi[INVESTIGATOR_134176]; CT sc an 
of the brain can be performed if MRI of the brain is not feasible  
• Daily 30-minute EEG until toxicity symptoms resolve; if no seizures are detected on EEG, 
continue levetiracetam 750 mg every 12 hours  
• If EEG shows non-convulsive status epi[INVESTIGATOR_7397], treat as per algorithm in Table 7   
• Consider anti-IL-6 therapy with tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV, if 
encephalopathy is associated with concurrent CRS  
Grade 2 
 • Supportive care and neurological work-up as described for grade 1 encephalopathy  
• Tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV if associated with concurrent CRS  
• Dexamethasone 10 mg IV every 6 hours or methylprednisolone 1 mg/kg IV every 12 hours if 
refractory to anti-IL-6 therapy, or for encephalopathy without concurrent CRS  
• Consider transferring subject to ICU if encephalopathy associated with Grade ≥2 CRS  
Grade 3 
 • Supportive care and neurological work-up as indicated for Grade 1 encephalopathy 
• ICU transfer is recommended  
• Anti-IL-6 therapy if associated with concurrent CRS, as described for Grade 2 encephal opathy 
and if not administered previously  
• Corticosteroids as outlined for Grade 2 encephalopathy if symptoms worsen despi[INVESTIGATOR_6698]-IL- 6 
therapy, or for encephalopathy without concurrent CRS; continue corticosteroids until 
improvement to Grade 1 encephalopathy and then taper  
• Stage 1 or 2 papi[INVESTIGATOR_134177] <20 mmHg should be treated as per 
algorithm presented in Table 8 
• Consider repeat neuroimaging (CT or MRI) every 2 –[ADDRESS_1176762] has persistent grade ≥3 
encephalopathy 
Grade 4 
 • Supportive care and neurological work-up as outlined for Grade 1 encephalopathy  
• ICU monitoring; consider mechanical ventilation for airway protection  
• Anti-IL-6 therapy and repeat neuroimaging as described for Grade 3 encephalopathy   
• High-dose corticosteroids continued until improvement to Grade 1 encephalopathy and then 
taper; for example, methylprednisolone IV 1 g/day for 3 days, followed by [CONTACT_134236] 250 
mg every 12 hours for 2 days, 125 mg every 12 hours for 2 days, and 60 mg every 12 hours 
for 2 days  
• For convulsive status epi[INVESTIGATOR_7397], treat as per algorithm in Table 7   
• Stage ≥3 papi[INVESTIGATOR_59411], with a CSF opening pressure ≥20 mmHg or cerebral oedema, should 
be treated as per algorithm in Table 8 
CAR, chimeric antigen receptor; CSF, cerebrospi[INVESTIGATOR_872]; CRS, cytokin e release syndrome; CT, computed tomography 
(scan); EEG, electroencephalogram; ICU, intensive care unit; IV, intraven ous; MRI, magnetic resonance imaging. 
 a Maximum amount of tocilizumab per dose is 800 mg. 
Reference: Neelapu 2018.  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 43 of 79 MT2020-33  
Table 7: Recommendations for the Management of Status Epi[INVESTIGATOR_846348]-convulsive 
status epi[INVESTIGATOR_7397]  
 • Assess airway, breathing, and circulation; check blood glucose  
• Lorazepam a 0.5 mg IV, with additional 0.5 mg IV every 5 minutes, as needed, 
up to a total of 2 mg to control electrographical seizures  
• Levetiracetam 500 mg IV bolus, as well as maintenance doses  
• If seizures persist, transfer to ICU and treat with phenobarbital loading dose of 
60 mg IV  
• Maintenance doses after resolution of non-convulsive status epi[INVESTIGATOR_846349]: lorazepam 0.5 mg IV every 8 hours for three doses; levetiracetam 
1,000 mg IV every 12 hours; phenobarbital 30 mg IV every 12 hours  
Convulsive status 
epi[INVESTIGATOR_7397]  
 • Assess airway, breathing, and circulation; check blood glucose  
• Transfer to ICU  
• Lorazepam a 2 mg IV, with additional 2 mg IV to a total of 4 mg to control 
seizures  
• Levetiracetam 500 mg IV bolus, as well as maintenance doses  
• If seizures persist, add phenobarbital treatment at a loading dose of 
15 mg/kg IV  
• Maintenance doses after resolution of convulsive status epi[INVESTIGATOR_134180]: 
lorazepam 0.5 mg IV every 8 hours for three doses; levetiracetam 1,000 mg IV 
every 12 hours; phenobarbital 1 –3 mg/kg IV every 12 hours  
• Continuous electroencephalogram monitoring should be performed, if seizures 
are refractory to treatment  
ICU, intensive care unit; IV, intravenous. 
NOTE: All indicated doses of medication are for adult subjec ts.  
a Lorazepam is the recommended benzodiazepi[INVESTIGATOR_846350]-acting, compared with diazepam, and has been widely 
used in the management of seizures.  
Reference: Neelapu 2018. 
 
 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 44 of 79 MT2020-33  
Table 8: Recommendation for the Management of Raised Intracranial Pressure (ICP) 
Stage Management 
Stage 1 or 2 papi[INVESTIGATOR_044] a with CSF 
opening pressure of <20 mmHg without 
cerebral edema  • Acetazolamide 1,000 mg IV, followed by 250 –1,000 mg IV 
every 12 hours (adjust dose based on renal function and 
acid-base balance, monitored 1 –2 times daily)  
Stage 3, 4, or 5 papi[INVESTIGATOR_59411], a with any 
sign of cerebral oedema on imaging 
studies, or a CSF opening pressure of  
≥20 mmHg  
 • Use high-dose corticosteroids with methylprednisolone IV 
1 g/day, as recommended for Grade 4 encephalopathy 
syndrome (Table 6)  
• Elevate head end of the subject’s bed to an angle of 
30 degrees  
• Hyperventilation to achieve target partial pressure of arterial 
carbon dioxide (PaCO2) of 28 –30 mmHg, but maintained for 
no longer than 24 hours  
• Hyperosmolar therapy with either mannitol (20 g/dL solution) 
or hypertonic saline (3% or 23.4%, as detailed below) 
− Mannitol: initial dose 0.5 –1 g/kg; maintenance at  
0.25–1 g/kg every 6 hours while monitoring metabolic 
profile and serum osmolality every 6 hours, and withhold 
mannitol if serum osmolality is ≥320 mOsm/kg, or the 
osmolality gap is ≥40  
− Hypertonic saline: initial 250 mL of 3% hypertonic saline; 
maintenance at 50 –75 mL/h while monitoring electrolytes 
every 4 hours, and withhold infusion if serum Na levels 
reach ≥155 mEq/L  
− For subjects with imminent herniation: initial 30 mL of 
23.4% hypertonic saline; repeat after 15 minutes, if 
needed  
• If subject has ommaya reservoir, drain CSF to target opening 
pressure of <20 mmHg  
• Consider neurosurgery consultation and IV anesthetics for 
burst-suppression pattern on electroencephalography  
• Metabolic profiling every [ADDRESS_1176763] scan of head, 
with adjustments in usage of the aforementioned medications 
to prevent rebound cerebral edema, renal failure, electrolyte 
abnormalities, hypovolemia, and hypotension  
CSF, cerebrospi[INVESTIGATOR_872]; CT, computed tomography (scan); IV , intravenous. 
NOTE: All medication doses indicated are for adults.  
a Papi[INVESTIGATOR_134182]Øn scale. 
Reference: Neelapu 2018.  
7.[ADDRESS_1176764] not been associate d 
with GvHD. ( Veluchamy 2017 ). 
 
Acute GvHD assessments will be performed with assignment of the overall 
severity based on the CIBMTR acute GvHD grading scale (Table 9). 
Management of GvHD should be done in accordance with local institutional 
practice. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 45 of 79 MT2020-33 Acute GvHD will be assessed according to criteria established by [CONTACT_846380] (Table 9). 
 
Management of GvHD should be done in accordance with local institutional 
practice. 
 
Table 9: GVHD Grading and Staging  
Source: https://www.cibmtr.org/manuals/fim/1/en/topic/f2100 -q131-[ADDRESS_1176765] 20, 2020.  
Extent of Organ Involvement 
Stage Skin Liver Gut 
1 Rash on <25% of skin1 Bilirubin 2-3 
mg/dl2 Diarrhea > 500 ml/day3 or persistent 
nausea4 
Pediatric : 280-555 ml/m2/day or 10-19.9 
mL/kg/day 
2 Rash on 25-50% of skin Bilirubin 3-6 
mg/dl Diarrhea >1000 ml/day 
Pediatric : 556-833 ml/m2/day or 20-30 
mL/kg/day 
3 Rash on >50% of skin Bilirubin 6-15 
mg/dl Diarrhea >1500 ml/day 
Pediatric : >833 ml/m2/day or > 30 
mL/kg/day 
4 Generalized erythroderma with 
bullous formation Bilirubin >15 
mg/dl Severe abdominal pain, with or without 
ileus, and / or grossly blood stool 
Grade5 
I Stage 1-2 None None 
II Stage 3 Stage 1 Stage 1 
III — Stage 2-3 Stages 2-4 
IV6 Stage 4 Stage 4 — 
1 Use “Rule of Nines” (see Percent Body Surfaces tabl e below) or burn chart to determine extent of rash. 
2 Range given as total bilirubin. Downgrade one stag e if an additional cause of elevated bilirubin has been 
documented. 
3 Volume of diarrhea applies to adults. For pediatri c patients, the volume of diarrhea should be based on body 
surface area. Downgrade one stage if an additional cause of diarrhea has been documented. 
4 Persistent nausea with or without histologic evide nce of GVHD in the stomach or duodenum. 
5 Criteria for grading given as minimum degree of or gan involvement required to confer that grade. 
6 Grade IV may also include lesser organ involvement  with an extreme decrease in performance status 
7.7 Tumor Lysis Syndrome (TLS) 
TLS is a possible risk associated with anti-tumor therapy however the risk of TL S 
on this protocol is exceedingly low because patients have received recent high-
dose chemotherapy and tumor bulk at time of autologous stem cell transplan t is 
low. TLS symptoms include nausea, vomiting, diarrhea, muscle cramps or 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176766] been rep orted 
to cause myelosuppression (neutropenia and/or thrombocytopenia), leukopenia, 
anemia; and in some cases, bone marrow failure. Hematologic cytopenias could  
be further compounded by [CONTACT_532853], con current 
illnesses and concomitant medications.  
Close monitoring of complete blood count (CBC) and for the deve lopment of 
infections is strongly recommended. In general, management including transfusion 
support and use of growth factors, should be done in accordance with stand ard 
institutional practice.  
7.[ADDRESS_1176767] clinically, e.g., as infusion-
related reactions with varying degrees of severity, including serious life-threat ening 
anaphylactic reactions. AEs arising from FT538 immunogenicity will be mana ged 
per institutional practice.   
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 47 of 79 MT2020-33 8 Schedule of Treatment, Tests, and Procedures 
“Clinic visits” may be done by a virtual visit or by [CONTACT_648], email, or text to a ssess general 
status, review lab results, and any ongoing adverse events. 
 
A minimum of [ADDRESS_1176768] dose of FLU and the  FT538 infusion. 
There is no Day 0 in this treatment schema. 
 
A – 1 Day window is permitted for the FT538 infusion to permit some flexibility o f 
scheduling for individual patients. 
 
A – 1 Day window is permitted for visits until the End of Treatment (EOT) a ssessment; 
however, whenever feasible do not shift subsequent future time points off o f the 
targeted day.  
 
The End of Treatment assessment occurs no sooner than Day 29 (+3 days) as this is 
coincides with the end of DLT period.  
 
After Day 29, follow-up assessments are associated with the closest standard of car e 
visit. The Day 42 follow-up is the final monitoring for excessive toxicity. 
 
In addition, targeted days may be altered as clinically appropriate. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 48 of 79 MT2020-33 8.1 Required Clinical Care Evaluations 
Bold  – investigational agent 
treatment day Screening / 
Baseline Day 
-6 Day 
-5 Day  
-4  Day 
-3 Day 
-2 Day 
1 Day 
2 Day 
3 Day 
8 Day 
15 Day 
22 
 Day 29 
EOT/ end 
of DLT 
 Day 42 
(~end of 
SR period) 3, 6, 9, and [ADDRESS_1176769]  
FT538 infusion7 Light – Daratumumab 
Bold shade – FT-538 
Consent  X1               
Screening Assessment  X               
Brief Medical Assessment   X    X X  X X X X   
Medical History  X              X 
Concomitant Medications10 X  X    X  X    X   
Assess Venous Access X               
Physical Exam  X X X X X X         X 
Daratumumab   X             
Fludarabine  X X X X X          
Cytoxan    X X           
FT-538       X   X X     
Prophylaxis for Herpes Zoster 
Reactivation X (start per 
Section 6.1 )               
ICANS (neurotoxicity)6 
monitoring – refer to Section 
7.5   
    
X X  X X X X  X 
KPS or Lansky Play score X               
Weight  X   X            
Height  X               
Vitals and Pulse Oximetry  X  X    X5 X X X5 X5 X5 X   
Toxicity Assessment in person 
or patient reported and survival 
status  X  
X    
X X  X X X X X X 
CBC, diff, plt  X  X    X X  X X X X X X 
Basic metabolic panel (BMP)1        X        
Comprehensive metabolic 
panel (CMP)[ADDRESS_1176770] 
for WOCBP3 X               
If CRS is suspected or 
diagnosed       X   
If patient develops neurotoxicity       X11   
Disease staging8 X           X†   Per SOC 
Bone marrow aspi[INVESTIGATOR_337]         X       
CXR or chest CT scan  X               
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 49 of 79 MT2020-33 Bold  – investigational agent 
treatment day Screening / 
Baseline Day 
-6 Day 
-5 Day  
-4  Day 
-3 Day 
-2 Day 
1 Day 
2 Day 
3 Day 
8 Day 
15 Day 
22 
 Day 29 
EOT/ end 
of DLT 
 Day 42 
(~end of 
SR period) 3, 6, 9, and [ADDRESS_1176771]  
FT538 infusion7 Light – Daratumumab 
Bold shade – FT-538 
PFTs4 X               
LVEF by [CONTACT_846381]  X               
SOC of assessment for history 
or suspected CNS involvement 
per Section 4.3.7  X               
1 basic metabolic panel consists of BUN, creatinine, calcium, glucose, lytes (CO2, Cl, Na, K)  
2 comprehensive metabolic panel consists of albumin, alkaline  phosphatase (ALP), alanine aminotransferase (ALT), aspar tate aminotransferase (AST), blood urea nitrogen (BUN),  calcium, 
creatinine, glucose, lytes (CO2, Cl, Na,, K), total bilirub in, and total protein 
3 women of child bearing potential – negative test must be obtained within 14 days prior to dos e of daratumumab 
4 pulmonary function testing required only if symptomatic or p rior known impairment 
5 Vital signs (temperature, systolic and diastolic blood press ure, heart rate, and respi[INVESTIGATOR_1487]) are performed in ass ociation with the FT538 infusion at the following time points: with in 
15 minutes of the infusion start, at 10 (–5) minutes dur ing infusion, and every 15 (–5) minutes for [ADDRESS_1176772] treatmen t. If the patient develops neurological toxicity for which c erebrospi[INVESTIGATOR_872] (CSF) analysis is performed, in addition to s tandard 
clinical testing, the sample should be tested for Human Herpes Virus (HHV 6&7) per Section 7.5 . In addition, quantitative testing in blood for HHV6 and H HV7 in the context of neurotoxicity 
should be done.  
7 Long-term follow-up continues for up to 15 years  
8 BM aspi[INVESTIGATOR_337]/biopsy with flow, cytogenetics, NGS, and target ed molecular diagnostics. At time of each SOC BM bx collect re search related aspi[INVESTIGATOR_846351] a green top tube – to TTL 
† BM aspi[INVESTIGATOR_846352] 2 5 +/- [ADDRESS_1176773] be done within 1 4 days prior to daratumumab. 
10  Hydroxyurea as used in the study is considered sup portive care per Section 6.4, not as an anti-cancer a gent  
11  ICANS assessments will only be required in the follow u p period if clinically indicated, and may be discontinued upon patient’s  return to baseline.  
 
 
 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 50 of 79 MT2020-33 8.2 Research Related Tests and Procedures 
 
Baseline 
prior to 
study 
treatment   Prior to 
DARA 
D-5 During FT538/DARA Day 22 End of treatment 
Visit (end of DLT 
period)  
Day 29 End of excess 
toxicity period  
~Day [ADDRESS_1176774] dose 
of FT538 at time of 
SOC visit 
Prior to 
FT538 
#1 Day 1 Day 2 Day 3 Prior to 
FT538 #2 
Day 8 Prior to 
FT538 #3 
Day 15    
 
ferritin, CRP (to hospi[INVESTIGATOR_846353])1 X        X   
Assess for toxicity (including DLTs 
and SRs) per Section 10   X X X X X X X X X X 
Six 10 ml green top tubes2 X X X X  X X X X  X (30 mL) 
One 10 ml of red top tube  X X X X  X X X X  X (10 mL) 
One 10 ml green top tube2 30 (– 
5) minutes post FT538 infusion 
end   X (post 
FT538)   X (post 
FT538) X (post 
FT538)    
 
One 10 ml green top tube2    X X       
Baseline safety samples:  
1 x 3 ml red top serum tube  
1 x 10 ml green top tube 
– store frozen in TTL and batch 
ship to Fate X     
     
 
Safety follow-up:  
1 x 3 ml red top serum tube  
1 x 10 ml green top tube 
– store frozen in TTL and batch 
ship to Fate         
  
X (at 3, 6, and 12 
months only) 
At time of each bone marrow 
biopsy and/or aspi[INVESTIGATOR_337], collect 
aspi[INVESTIGATOR_846351] a green top 
tube for research X    
X3   
X4   
X 
PRA anti-HLA antibodies  
one 10 ml red top (to hospi[INVESTIGATOR_846353]) X     
   X  
 
Note: enrollment to this study is for patients 50 kg or greater. Adjustment to research blood volumes (weigh t based) is not required for pediatric patients. 
1 - refer to Section 8.1  and Section 7.4  for at the time CRS is suspected and if definitive diagnosis is made 
2 - At TTL: PBMCs are isolated from the heparin/green tube for PCR testing by [CONTACT_622831].  
3 - –[ADDRESS_1176775] follow FT538 infusion                                                                                                 4- BM biopsy for disease assessment to occur on day 25–4 days.  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 51 of 79 MT2020-33 All research samples go to the Masonic Cancer Center’s Translational Therapy Lab (TTL) 
except for the baseline and Day [ADDRESS_1176776]- PRA anti-HLA antibodies samples which are charged to research but run in the 
treatment center’s clinical lab.  
 
Note:  if a patient is not abiding by [CONTACT_134220] ( Section 8.1 ), the 
collection schedule of research related samples may be altered or deleted or discontinued 
on an individual patient basis, as appropriate. During follow-up no visit wi ll be solely for 
research and instead be linked with a standard of care visit closest to the targ eted research 
related time point.  
 
It is recognized that with novel therapi[INVESTIGATOR_134159], the timing of pro tocol 
directed research samples may miss important patient specific events. For this reaso n, 
research samples may be collected at up to 3 extra time points that are not specified 
above.  
 
Samples to evaluate lymphocyte number and phenotype will be collected a s detailed 
above for the Masonic Cancer Center Translational Therapy Lab (TTL) alon g with serum 
(red top tubes) for measure of cytokines that can reflect immune activation.  
 
Samples may be sent to laboratories outside of the University of Minnesota in ca ses where 
testing is not available internally, as embedded in the patient consent form. 
 
Flow cytometry analysis of a fraction of the PBMC will detect surface markers that define 
lymphocyte subsets (NK, NKT, B, and T cells, both CD4 and CD8), as well as intracellular 
markers that define regulatory T cells (Foxp3) and proliferating cells (Ki67).  
 
Any remaining PBMC will be cryopreserved in 10% DMSO and stored in liqu id nitrogen for 
future testing, if the patient agreed to future storage at the time of initial consent.  
[ADDRESS_1176777] and can only be used and administered under an 
FDA-approved protocol. For the purposes of this study FT538 is provided by [CONTACT_846382].  
9.1.1 Availability   
FT538 will be supplied by [CONTACT_846383]. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176778] Lot #, Bag ID #, and amount of VC. The label will also contain the follo wing 
statement: “Caution: New Drug –  Limited by [CONTACT_36974].”  
9.1.3 Storage  
FT538 is stored at the University of Minnesota Molecular and Cellular Therapeutics 
(MCT).  
 
FT538 must be stored in the vapor phase of liquid nitrogen (VPLN2) at ≤ -150°C, in a 
continuously temperature-monitored and alarmed VPLN2 freezer in a controlle d-
access room with limited personnel access. Temperature excursions up to -135°C for 
10 minutes due to normal equipment use (e.g., opening and closing  of the storage unit) 
are allowed.  
9.1.[ADDRESS_1176779] is aseptically filled into pre-sterilized, single-use 
cryopreservation bags.  
9.1.5 Route of Administration 
FT538 is thawed and administered as an IV infusion via gravity. The following are 
acceptable forms of IV access in order of preference: 
1. Central venous catheter (CVC; e.g., Hickman) 
− Do not use implanted ports.  
2. Non-valved peripherally inserted central catheter (PI[INVESTIGATOR_6875]) 
3. Large-bore (18-gauge) straight IV needle 
9.1.6 Potential Toxicities 
Refer to Section 7  for potential toxicities. 
 
Refer to the current FT538 Investigator Brochure for additional information.  
9.2 Daratumumab 
9.2.1 Other names 
DARZALEX FASPRO ™ (daratumumab and hyaluronidase-fihj) injection 
9.2.2 Description 
DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic 
antibody, and hyaluronidase, an endoglycosidase 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 53 of 79 MT2020-33 9.2.3 FDA Approved Indications 
DARZALEX FASPRO is approved for the treatment of adult patients with multiple  
myeloma (April 2020). 
9.2.4 Availability  
A commercial formulation of daratumumab is purchased through the site’s 
Investigational Pharmacy for this study. 
9.2.5 How Supplied and Storage 
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection is a steri le, 
preservative-free, colorless to yellow, and clear to opalescent solution for 
subcutaneous use supplied as individually packaged single-dose vials providing 1 ,800 
mg of daratumumab and 30,000 units of hyaluronidase per 15 mL (N DC [ZIP_CODE]-503-
01). 
 
Store DARZALEX FASPRO vials in a refrigerator at 2”C to 8”C (36”F to 46”F) in the  
original carton to protect from light. 
 
Do not freeze or shake. 
9.2.6 Preparation and Administration 
DARZALEX FASPRO is ready to use. 
• Remove the DARZALEX FASPRO vial from refrigerated storage [2°C to 8°C 
(36°F to 46°F)] and equilibrate to ambient temperature [15°C to 30°C (59°F to 
86°F)]. Store the unpunctured vial at ambient temperature and ambient light for 
a maximum of [ADDRESS_1176780] sunlight. Do not shake. 
• Withdraw 15 mL from the vial into a syringe. 
• DARZALEX FASPRO is compatible with polypropylene or polyethylene syringe 
material; polypropylene, polyethylene, or polyvinyl chloride (PVC) subcutaneous 
infusion sets; and stainless steel transfer and injection needles. Use the product 
immediately. 
• After the solution of DARZALEX FASPRO is withdrawn into the syringe, replace 
the transfer needle with a syringe closing cap. Label the syringe  appropriately 
to include the route of administration per institutional standards. Label the 
syringe with the peel-off label. 
• To avoid needle clogging, attach the hypodermic injection needle or 
subcutaneous infusion set to the syringe immediately prior to injection. 
• Parenteral drug products should be inspected visually for particulate matter and 
discoloration prior to administration, whenever solution and container permit. Do 
not use if opaque particles, discoloration or other foreign particles are present.  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 54 of 79 MT2020-33 Storage of prepared syringe: 
• If the syringe containing DARZALEX FASPRO is not used immediately, sto re 
the DARZALEX FASPRO solution for up to [ADDRESS_1176781] after 4 hours, if not used. 
Administration: 
• Inject 15 mL DARZALEX FASPRO into the subcutaneous tissue of the ab domen 
approximately 3 inches [7.5 cm] to the right or left of the navel over 
approximately 3-5 minutes. No data are available on performing the injection a t 
other sites of the body. 
• Rotate injection sites for successive injections. 
• Never inject DARZALEX FASPRO into areas where the skin is red, bruised, 
tender, hard or areas where there are scars. 
• Pause or slow down delivery rate if the patient experiences pain. In the  event 
pain is not alleviated by [CONTACT_846377], a second 
injection site may be chosen on the opposite side of the abdomen to  deliver the 
remainder of the dose. 
• During treatment with DARZALEX FASPRO, do not administer other 
medications for subcutaneous use at the same site as DARZALEX FASPRO. 
9.2.7 Potential Toxicities 
Warnings and Precautions:  
• Hypersensitivity and Other Administration Reactions: Permanently discontinue 
DARZALEX FASPRO for life-threatening reactions.  
• Neutropenia: Monitor complete blood cell counts periodically during treat ment. 
Monitor patients with neutropenia for signs of infection. Consider withholding 
DARZALEX FASPRO to allow recovery of neutrophils.  
• Thrombocytopenia: Monitor complete blood cell counts periodically during 
treatment. Consider withholding DARZALEX FASPRO to allow recovery of 
platelets.  
• Embryo-Fetal Toxicity: Can cause fetal harm. Advise pregnant women of the 
potential risk to a fetus and advise females of reproductive potential to use 
effective contraception. Males and females should use effective contraceptio n 
for at least [ADDRESS_1176782] dose of drug. 
• Interference with cross-matching and red blood cell antibody screening: Typ e 
and screen patients prior to starting treatment. Inform blood banks that a patient 
has received DARZALEX FASPRO.  
 
Potential Risks: 
May be serious 
• Serious allergic reactions and other severe injection-related reactions. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 55 of 79 MT2020-33 • Injection site reactions 
• Decrease in blood counts 
• Changes in blood type testing for up to [ADDRESS_1176783] when used as monotherapy included cold-like 
symptoms (upper respi[INVESTIGATOR_4416]). 
10 Adverse Event Monitoring, Documentation, and Reporting 
For the purposes of the study the FT538 and daratumumab are considered investig ational 
products. 
 
Toxicity and adverse events will be classified and graded according to NCI’s Common 
Terminology Criteria for Adverse Events V 5.0 (CTCAE) and reported on the sch edule 
below. A copy of the CTCAE can be downloaded from the CTEP home page.   
(https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Q
uick_Reference_5x7.pdf) 
 
An exception to the use of CTCAE will be for the assessment of cyto kine release syndrome 
(CRS). Individual adverse events which are associated with CRS will be graded per 
CTCAE; however the ultimate assessment will be made using a revised grading  system 
for CRS as presented by [CONTACT_43265] ( Lee 2019 ).  
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 56 of 79 MT2020-33 Table 10: ASTCT Cytokine Release Syndrome Consensus Grading System a 
CRS Parameter  Grade 1  Grade 2  Grade 3  Grade 4  
Fever b Temperature ≥38˚C  Temperature ≥38˚C  Temperature ≥38˚C  Temperature ≥38˚C  
With either: 
Hypotension None Not requiring 
vasopressors Requiring 
vasopressors 
with/with-out 
vasopressin Requiring multiple 
vasopressors 
(excluding 
vasopressin) 
And/or c 
Hypoxia None Requiring low-flow 
nasal cannula d or 
blow-by [CONTACT_13198]-flow 
nasal cannula, 
facemask, 
non-rebreather mask, 
or venturi mask Requiring positive 
pressure 
(e.g., CPAP, 
BiPAP, intubation 
and mechanical 
ventilation) 
ASTCT, American Society for Transplantation and Cellular Therapy; BiP AP, bilevel positive airway pressure; 
CPAP, continuous positive airway pressure; CRS, cytokine release s yndrome; NCI CTCAE, National Cancer 
Institute Common Terminology Criteria for Adverse Events. 
a Organ toxicities associated with CRS may be graded according to NCI CTCAE v 5.0, but they do not influence 
CRS grading. 
b Fever is defined as temperature ≥38°C not attributable to any other cause. In subjects who have CRS th en 
receive antipyretics or anti-cytokine therapy such as tociliz umab or steroids, fever is no longer required to grade 
subsequent CRS severity. In this case, CRS grading is driven by h ypotension and/or hypoxia. 
c CRS grade is determined by [CONTACT_13200]: hypotension or hyp oxia not attributable to any other cause. 
For example, a subject with temperature of 39.5°C, hypotension requirin g one vasopressor and hypoxia 
requiring low flow nasal cannula is classified as having Grade 3 CRS. 
d Low-flow nasal cannula is defined as oxygen delivered at >6 liters/minute. Low flow also includes blow-by 
[CONTACT_13201], sometimes used in pediatrics. High-flow nasa l cannula is defined as oxygen delivered at 
>6 liters/minute. 
Source : Lee et al. 2019 . 
 
The following definitions of adverse events (AEs) and serious adverse eve nts (SAEs) will 
determine whether the event requires expedited reporting via the OnCore SAE  Report 
Form in addition to routine documentation in the OnCore AE case report form (CRF).  
10.1 Adverse Event Terminology 
Adverse Event:  Any untoward medical occurrence associated with the use of a dru g 
in humans, whether or not considered drug related. 
 
Suspected Adverse Reaction: Any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event. For the purposes of IND safet y 
reporting, ‘reasonable possibility’ means there is evidence to suggest a causal 
relationship between the drug and the adverse event. A suspected a dverse reaction 
implies a lesser degree of certainty about causality than an adverse reaction. 
 
Adverse Reaction:  Any adverse event caused by a drug. Adverse reactions are a 
subset of all suspected adverse reactions where there is reason to conclude that th e 
drug caused the event. 
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 57 of 79 MT2020-33 Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R): Any adverse event  
meeting that meets the definition of serious for which there is a reasonable possibility 
that the drug caused the adverse event and it meets the definition of unexpected .  
 
Serious Adverse Event:  An adverse event is considered “serious” if, in the view of 
either the investigator or sponsor, it results in any of the following outcomes:  
• Death 
• A life-threatening adverse event 
• Inpatient hospi[INVESTIGATOR_1081] 
• A persistent or significant incapacity or substantial disruption of the abil ity to 
conduct normal life functions 
• A congenital anomaly/birth defect 
• An important medical event 
Important medical events that may not result in death, be life-threaten ing, or require 
hospi[INVESTIGATOR_708], based upon appropriate  medical 
judgment, they may jeopardize the patient or subject and may requ ire medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  
 
Unexpected Event: An adverse event or suspected adverse reaction is considered 
“unexpected” if it is not listed in the investigator brochure or is not listed at the 
specificity or severity that has been observed; or, if an investigator brochure is not 
required or available, is not consistent with the risk information described in the  
general investigational plan or elsewhere in the current application, as amended.  
 
Note: refer to the current FT538 Investigator Brochure for expected adverse events. 
For DARZALEX FASPRO ™ the current USPI [INVESTIGATOR_846354].  
 
The categories for AE attribution to study treatment are as follows:  
• Definite – clearly related 
• Probable – likely related 
• Possible – may be related 
• Unlikely – doubtfully related 
• Unrelated – clearly not related 
10.2 AE Monitoring and Event Documentation Requirements 
Adverse event documentation for the purposes of this study will focus on events fe lt to 
be related to FT538, daratumumab, or events that cannot be attribut ed to other causes 
(i.e., disease under treatment, co-morbidities). Adverse events can b e observed in 
person, abstracted from the medical record or patient reported. 
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176784] dose of FT538, whichever is later, based on the definition of excessive toxicity 
(stoppi[INVESTIGATOR_004] (SRs)). Once beyond the SR period, monitoring for adverse eve nts will 
become less frequent based on the schedule in Section 8.[ADDRESS_1176785] possibly related to FT538 will be documented upo n 
knowledge. 
 
Adverse event documentation for the purposes of this study will focus on  
• expected toxicities felt to be related to daratumumab 
• expected toxicities felt to be related to the FT538  
• events meeting the definition of a DLT or excessive toxicity per Section 10.4  
• any event meeting the definition of serious, regardless of attribution 
• unexpected adverse events that cannot be attributed to the disease und er treatment  
 
For the purposes of this study, adverse event documentation requiremen ts in OnCore 
will be based on grade, expectedness and relationship to the investigationa l product 
(FT538, daratumumab): 
 
 
Exceptions to AE Documentation: Laboratory abnormalities (e.g., clinical chemistry, 
hematology, and urinalysis) without clinical significance are not recorded as AE s or 
SAEs with the exception of abnormalities that meet the definition of DLT  per Section 
6.3.1 . Other abnormal assessments (e.g., vital signs, ECG, X-rays) that are not 
associated with signs or are considered of no clinical significance do not need to be 
recorded unless they are a dose limiting toxicity.  
 
Clinically significant is defined as requiring medical or surgical intervention or leading to 
a study treatment delay or discontinuation. Any laboratory or other assessmen ts 
meeting the definition of clinically significant must be recorded as an AE, as well as an  Grade 1 Grade 2 Grade 3 Grade 4 and 5 
Expected or 
Unexpected Expected Unexpected Expected Unexpected Expected or 
Unexpected 
Unrelated 
Unlikely  Not required Required Required Required Required Required 
Possible 
Probable 
Definite  Not required Required Required Required Required Required 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, [ADDRESS_1176786] death due to disease (see section 10.5) 
10.4 Dose Limiting Toxicity and Excessive Toxicity (Stoppi[INVESTIGATOR_134145]) 
Documentation and Reporting Requirements 
All patients are monitored for dose limiting toxicity (DLT) and excessive toxicity (earl y 
stoppi[INVESTIGATOR_206319]). Refer to Section 6.3.1  and Section 6.3.2  for definitions. 
 
In addition to documenting the event in the study’s CRF’s, all DLT  and SR events are 
to be documented on the Event Form found in OnCore per Mason ic Cancer Center 
procedures. 
 
An event that counts as a DLT does not necessarily constitute a SAE and should be 
reported as such only if they meet the criteria for reporting as defined in Section 10.3 . 
10.5 Documentation of Death and Reporting Requirements 
Deaths during the treatment and follow-up period that are not due to  AML will be 
recorded as an SAE and reported per Section 10.6 . Deaths due to patient’s underlying  
disease need not be recorded as SAEs, but should be recorded as a grade [ADDRESS_1176787] the cause. 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 60 of 79 MT2020-33 10.6 Expedited MCC Reporting Requirements  
As the study sponsor, the Masonic Cancer Center has the following expedited reporting 
responsibilities: 
[ADDRESS_1176788] regulatory and clinical data using University of Minnesota CTSI’s 
instance of OnCoreﬁ (Online Enterprise Research Management Environment).  
 
The OnCore database resides on dedicated secure and PHI compliant servers. All 
relevant AHC IS procedures related for PHI compliant servers (as required by [CONTACT_846384]/email 
address 
Advarra  (IRB 
of Record) unanticipated problems involving risks to subjects or 
others; unanticipated adverse device 
effects; protocol violations that may affect the 
subjects’ rights, safety, or well -being and/or the 
completeness, accuracy and reliability of the study 
data; subject death not related to primary 
malignancy; suspension of enrollment; or 
termination of the study  promptly and no later than 
2 weeks (10 business 
days) from the time the 
investigator learns of the 
event Refer to the 
Advarra IRB 
Handbook 
Advarra via study 
specific CIRBI Link 
UMN IRB Refer to Submitting Updates in ETHOS – External IRB Study/Site 
FDA 
 Unexpected and fatal or unexpected and life 
threatening suspected adverse reaction no later than 7 Calendar 
Days MCC SAE Report 
Form Submit to FDA as an 
amendment to IND  
with a copy to Fate 
Therapeutics within 
1 business day of 
FDA reporting 
pv@fatetherapeutic
s.com 
 1) Serious and unexpected suspected adverse 
reaction or 
2)  increased occurrence of serious suspected 
adverse reactions over that listed in the protocol or 
investigator 
brochure or 
3) findings from other sources (other studies, animal 
or in vitro testing) no later than 15 Calendar-
Days 
1) All other events per CFR 312.33 
2 )An annual manufacturing update, including for 
each new lot of the investigational biologic used in 
clinical trials, the lot number, the results of all tests 
performed on the lot, and the specifications when 
established (i.e., the range of acceptable results) (21 
CFR 312.23(a)(7))  At time of IND annual 
report Summary format Submit as part of 
the IND annual 
report 
U of MN 
Institutional 
Biosafety 
Committee Any significant research-related accidents and 
illnesses involving potentially hazardous biological 
agents subject to IBC purview As soon as possible 
(within 24 hours is ideal) IBC Incident 
Report Via eProtocol 
Fate 
Therapeutics Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) Within 3 business days of 
knowledge MCC SAE Report 
Form  Fate Therapeutics at 
pv@fatetherapeutics.
com 
All other SAE’s  Within 5 business days of 
knowledge 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 61 of 79 MT2020-33 Center of Excellence for HIPAA Data) apply to OnCore databases. The infor matics 
team grants the IRB approved study team members access to data. 
 
Additional immune monitoring data about correlative laboratory samples generated by 
[CONTACT_337591] (TTL) from the p rotocol-
directed correlative research samples is stored in their Laboratory Information 
Management System (LIMS). The LIMS database application is also stored on a  
production server located in the UMN datacenter (WBOB) and is managed by [CONTACT_846385]. 
11.2 Case Report Forms 
Participant data will be collected using protocol specific electronic case report forms 
(e-CRFs) developed within OnCore based on its library of standardized forms. The  e-
CRF will be approved by [CONTACT_1758]’s Principal Investigator [INVESTIGATOR_337558]. The Study Coordinator or designee will be responsible for reg istering 
the patient into OnCore at time of study entry, completing e-CRFs based o n the patient 
specific calendar, and updating the patient record until patient death or en d of required 
study participation.  
11.3 Data and Safety Monitoring Plan (DSMP) 
The study’s Data and Safety Monitoring Plan will be in compliance with the  University 
of Minnesota Masonic Cancer Center’s Data & Safety Monitoring Plan (DSMP ), which 
may be accessed at http://z.umn.edu/dsmp  
 
For the purposes of data and safety monitoring, this study is classified as hi gh risk 
(under a locally held IND). Therefore, the following requirements will be fulfil led at the 
University of Minnesota and at participating sites: 
▪ At least quarterly review of the study’s progress by [CONTACT_137249] (DSMC). 
▪ The University of Minnesota (lead site) Principal Investigator [INVESTIGATOR_846355]. 
 
IND Annual Reports 
In accordance with regulation 21 CFR § 312.33, the IND S/I ([CONTACT_846392]) will submit 
a progress report annually. The report is submitted within [ADDRESS_1176789]. A copy of the report will be provide d to Fate 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 62 of 79 MT2020-33 Therapeutics. Additional annual reporting requirements are found in the FDA  
Acknowledgment of Receipt of IND.  
 
11.4 Site Monitoring 
The investigator will permit study-related monitoring, audits, and inspections by t he 
study’s Principal Investigator /IND sponsor and/or any designees, the local IRB, 
government regulatory bodies, and University of Minnesota compliance groups.  The 
investigator will make available all study related documents (e.g. source documen ts, 
regulatory documents, data collection instruments, study data, etc.). The  investigator 
will ensure the capability for inspections of applicable study-related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.) will be available for trial related monitori ng, 
audits, or regulatory inspections. 
11.[ADDRESS_1176790] Retention 
The investigator will retain study records including source data, copi[INVESTIGATOR_337561], consent forms, HIPAA authorizations, and all study correspondence  in a 
secured facility until permission is received that the documents are no longer needed.  
 
In addition, the Clinical Trials Office (CTO) will keep a master log in OnCore of all 
patients participating in the study with sufficient information to allow retrieval of the  
medical records for that patient.  
 
Please contact [CONTACT_102676]. 
12 Statistical Considerations  
12.1 Study Design, Objectives and Endpoints  
This is a Phase I study of FT538 for the treatment of patients with relapsed/refractory  
CD38 expressing hematological malignancies. The primary endpoint is the maximum 
tolerated dose (MTD) of FT538 when given in combination with daratumumab. 
 
The primary analysis will be intent-to-treat in that all patients receiving th e 1st infusion 
of FT538 will be evaluable for toxicity and efficacy. Patients who discontinue therapy 
prior to infusion #[ADDRESS_1176791] that the number of patients coming off 
therapy prior to infusion #1 will be minimal.  
 
There are 5 potential dose levels defined for Phase I. The trial will be  conducted with 
no intra-patient escalation. The starting dose will be 1x108 FT538 cells with a safety 
dose of 5x107 FT538 cells. The subsequent planned cohorts will be 3x108 FT538 cells, 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 63 of 79 MT2020-33 1x109 FT538 cells and 1.5 x109 FT538 cells ( Table 1) . Given that little to no toxicity is 
expected, the MTD will be determined using an adaptation of the continua l 
reassessment method (CRM) ( O’Quigley, 1996 ) starting with 1 patient cohorts.  
 
Table 1. FT538 Dose Level and Schedule 
Dose Level Treatment Plan for FT538 
-1 5 x 107 cells on Day 1, Day 8 and Day 15 
1 (start) 1 × 108 cells on Day 1, Day 8 and Day 15 
2 3 × 108 cells on Day 1, Day 8 and Day 15 
3 1 × 109 cells on Day 1, Day 8 and Day 15 
4 1.5 × 109 cells on Day 1, Day 8 and Day 15 
 
Phase I will be conducted in two consecutive stages (non-CRM and CRM ). A minimum 
of [ADDRESS_1176792] and 2nd patients. All patients are assessed for Dose Limiting 
Toxicity (DLT) as defined in the schema and Section 6.3.1. 
 
STAGE [ADDRESS_1176793]-track design (1 patient per dose cohort)  
Start at Dose Level 1 (DL1), enroll 1 patient per dose cohort separated by 28 days 
(DLT period) until the:  
• 1st pre-defined adverse event defined as any Grade 3 non-hematologic AE 
within 72 hours of a FT538 infusion  
• and the patient completes the 28 day DLT period with no DLT- Activate Stage 
1 Step 2  
OR  
• 1st DLT event within [ADDRESS_1176794] dose of FT538 as defined in the 
Schema and in Section 6.3.1 - Activate Stage 2 (Stage 1 Step 2 is not used)  
OR 
• 10 patients are treated at the Dose Level 4 (This completes enrollment - 
Stage 1 Step 2 and Stage 2 are not used) 
• If the first patient at dose level [ADDRESS_1176795] and the 2nd patient in 3 patient cohorts and a minimum of 28 days 
between dose cohorts. Continue dose escalation until: 
• 1st DLT event as defined in the Schema and Section 6.3.1 - Activate Stage 2  
OR  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 64 of 79 MT2020-33 • 10 patients are treated at the Dose Level 4  (This completes enrollment and 
Stage 2 is not used.) 
• For Dose Level [ADDRESS_1176796] DLT. The study design changes to an application of the 
continual reassessment method (CRM) with an informative skeleton based on  
constrained maximum likelihood estimation ( Iasonos & O’Quigley, 2012 ), (Iasonos & 
Ostrovnaya, 2011). Enrollment occurs in cohorts of three with a minimum of [ADDRESS_1176797] patient in a cohort reaches Day 28 (end of DLT 
period). The goal will be to identify one of the 5 dose level strategies corresponding  to 
the desired maximum toxicity rate of ≤25%. Given that we will have prior d ata once the 
CRM is initiated, no “skeleton” estimates are needed. The MTD will be identified by [CONTACT_846386]: (1) the total Stage 2 sample size of 25 is exhausted , 
(2) 10 consecutive patients are enrolled at the same dose. The function ‘crm’ from the 
R package ‘dfcrm’ will calculate posterior means of toxicity probabilities. Dose 
escalation of more than one level is not permitted with this design. 
12.2 Statistical Analysis 
The MTD will be determined by [CONTACT_8345]. Response will be estimated with simple 
proportions and descriptive plots. The secondary endpoints of overall survival and 
progression-free survival will be estimated with Kaplan-Meier curves. Safety meas ures 
will be described with frequencies and proportions. Further descriptive statistics and  
plots such as boxplots, spaghetti plots and swimmer plots will be used to assess 
kinetics and other markers of efficacy and toxicity. 
12.3 Sample Size 
A maximum of 25 patients will be enrolled during Phase I with a t arget DLT rate of 
≤25%. Based on the simulations from Table 11 , this should be sufficient and safe to 
define the MTD. Although complete skeleton estimates will not be determi ned until 
Stage 2, Table 11 is calculated based on hypothesized values.  
Table 11 . Operating characteristics for Adaptive-CRM  
 
Cells/ dose  Expected DLT, Expected 
SAE1,2 Excessive DLT, Excessive SAE  
True 
Probability  Prob. of 
dose3 N4 True 
Probability  Probability 
of dose  N 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 65 of 79 MT2020-33  
 
 
 
 
 
 
1. SAE’s without a DLT trigger step 2 in stage 1, DLT’s regardless of SAE’s trig ger stage 2  
2. Expected/Excessive values are the hypothesized true valu es under the simulation 
3. Probability of dose chosen as the MTD using the Adaptive-C RM design 
4. The hypothesized number of patients enrolled at each do se during the trial under the assumed hypothesized 
“true” probabilities  
 
Enrollment will most likely include 17 patients or it could be as high a s 25 patients if 
DLTs are encountered early.  
12.4 Monitoring Guidelines (Early Study Stoppi[INVESTIGATOR_1869]) 
Stoppi[INVESTIGATOR_134166] 
A stoppi[INVESTIGATOR_134167] I study to stop the tria l in case there are 
excessive DLTs as defined by [CONTACT_846387]. At 
the end of the 28-day evaluation period after each cohort of patients is enrolled, new 
posterior probabilities will be calculated for each dose. The trial will be stopp ed if the 
posterior probability that the lowest dose is unacceptably toxic (> 25% of patients) is 
greater than 80%. ( Zohar & Chevret, 2001 )  
 
Stoppi[INVESTIGATOR_846356]. (Ivanova, 2005 ).  
 
Infusion Related Reaction within [ADDRESS_1176798] 10% if the rate is equal to 5% and our 
sample size is at most 25. With these stipulations, the trial will be stopped and reviewed 
if 2/7, 3/[ADDRESS_1176799] events by [CONTACT_2006] 28. If the true probability of infusion related 
toxicity is 20%, there is an 82% chance of triggering the monitoring bounda ry. If the 
sample size is only 17 patients, the probability of triggering the mon itoring boundary 
drops to 67%.  
 
Aplasia at Day 42 (ANC <500) after at least 1 week of growth factor (i.e. G-CSF) 
with an aplastic bone marrow in the absence of leukemia (<5% cellularity) 
The goal is to construct a boundary based on aplasia such that the probability of early 
stoppi[INVESTIGATOR_429759] 10% if the rate is equal to 5% and our sample size is at m ost 25. 
With these stipulations, the trial will be stopped and reviewed if 2/7, 3/[ADDRESS_1176800] events by [CONTACT_2006] 42. If the true probability of aplasia is 20%, there is a n 82% chance 5 x 107 cells (-1)  1%, 2%  0% 0 15%, 18%  55% 13 
1 × 108 cells (1)  3%, 5%  0% 1 25%, 29%  37% 9 
3 × 108 cells (2)  6%, 8%  1% 3 45%, 50%  7% 3 
1 × 109 cells (3) 8%, 12% 1% 3 60%, 66% 1% 0 
1.5 × 109 cells (4) 10%, 15%  98% 10 70%, 77% 0% 0 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 66 of 79 MT2020-33 of triggering the monitoring boundary. If the sample size is only 17 pa tients, the 
probability of triggering the monitoring boundary drops to 67%. 
 
Early Death (Grade 5 Event) within [ADDRESS_1176801] dose of FT538 and not attributable to disease 
progression . At 25 patients, i f the true probability of early death is 5%, there is a 93% 
chance of triggering the monitoring boundary. If the sample size is only 17  patients, the 
probability of triggering the monitoring boundary drops to 73%.  
[ADDRESS_1176802] of the Study 
13.1 Good Clinical Practice 
The study will be conducted in accordance the appropriate regulatory requiremen t(s). 
Essential clinical documents are maintained to demonstrate the validity of the st udy 
and the integrity of the data collected. Master files should be established  at the 
beginning of the study, maintained for the duration of the study an d retained according 
to the appropriate regulations.  
13.[ADDRESS_1176803] the rights, safety and well-being of the patients. The s tudy will only 
be conducted at sites where IRB approval has been obtained. The protocol, consen t, 
written information given to the patients, safety updates, progress reports, and any 
revisions to these documents will be provided to the IRB by [CONTACT_737].  
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 67 of 79 MT2020-33 14 References 
Actemraﬁ (tocilizumab) injection, for intravenous or subcutaneous use [Prescribing Infor mation]. 
San Francisco, CA. Genentech, Inc.; 2019. 
American Association of Blood Banks (AABB). Circular of Information for the Use of  Human Blood 
and Blood Components. 2016. Available at: https://www.aabb.org/tm/coi/Documents/coi1017.pdf  
Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell l ine NK-92 in patients with 
advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625- 32.  
Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by  [CONTACT_846388]-2 diphtheria toxin fusion protein. Blood. 2014;123:3855- 63.   
Bachanova V, Sarhan D, Defor TE, et al. Haploidentical natural killer cells induce  remissions in non-
Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol  Immunother. 
2018;67:483-94.  
Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcRIIa-FcRIIIa polymorphisms and KRAS 
mutations on the clinical outcome of patients with metastatic colorectal cancer treated wi th cetuximab 
plus irinotecan. J Clin Oncol. 2009; 27:1122-29.  
Bjordahl R, Gaidarova S, Woan K, et al. Preclinical development of an off-the-shelf  adoptive NK cell 
immunotherapy with targeted disruption of CD38 to prevent anti-CD38 antibody-medi ated fratricide 
and enhance ADCC in multiple myeloma when combined with daratumumab. ASH Annual  Meeting, 
abstract 133. 2019.  
Bride, K.L, Vincent TL, Im SY, et.al. 2018. Preclinical efficacy of dar atumumab in T-cell acute 
lymphoblastic leukemia. Blood 131: 995-999. 
Brudno J, Kochenderfer J. Toxicities of chimeric antigen receptor T cells: reco gnition and 
management. Blood. 2016;127:3321-30. 
Buteyn N, Fatehchand, K, Santhanam R, et al. Anti-leukemic effects of all-trans r etinoic acid in 
combination with  Daratumumab in acute myeloid leukemia. International Immunology, V ol. 30, No. 
8, pp. 375 –383. 
Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 m onoclonal 
antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood. 2002;99:[ADDRESS_1176804]-in-human trial of rhIL-15 and haploidentical natural killer cell 
therapy for advanced acute myeloid leukemia. Blood Advances. 2019;3:1970-80.  
Cyclophosphamide for Injection, USP [Prescribing Information]. Deerfield, IL. B axter Healthcare 
Corporation; 2013.   
Dahlberg CI, Sarhan D, Chrobok M, et al. Natural killer cell-based therapi[INVESTIGATOR_846357]: possible 
strategies to gain and sustain anti-tumor activity. Front Immunol. 2015;6:605.  
Darzalex Fastpro ™ (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use 
[Prescribing Information]. Horsham, PA. Janssen Biotech, Inc, Issued 05/2020 asses sed at 
http://www.janssenlabels.com/package-insert/product-monograph/prescribing-
information/DARZALEX+Faspro-pi.pdf  September 28, 2020.  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 68 of 79 MT2020-33 Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in ad ults: [ADDRESS_1176805] 
recommendations from an international expert panel. Blood. 2017;129:424-47.  
Dos Santos C, Xiaochuan S, Chenghui Z, et. al. Anti-Leukemic Activity of Daratum umab in Acute 
Myeloid Leukemia Cells and Patient-Derived Xenografts. Blood (2014) 124 (21): 2312. 
Drach J, McQuuen T, Engel H. Retinoic Acid-induced Expression of CD38 Antigen in M yeloid Cells 
Is Mediated through Retinoic Acid Receptor- α. Cancer Research: April 1994 
Volume 54, Issue 7. 
Ganzel, C., M. Kharit, C. Duksin, and J. M. Rowe. 2018. Daratumumab for relapsed/refractory 
Philadelphia-positive acute lymphoblastic leukemia. Haematologica 103: e489-e490. 
Geller MA, Cooley S, Judson PL, et al. A Phase II study of allogeneic natural  killer cell therapy to treat 
patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98-107.   
Iasonos A.  Ostrovnaya  I. Estimating the dose-toxicity curve in completed phase I studies. Stat Med. 
2011 Jul 30;30(17):2117-29. doi: 10.1002/sim.4206. Epub 2011 Feb 22. 
Iasonos A, O’Quigley J. Interplay of priors and skeletons in two ‑stage continual reassessment method. 
Volume31, Issue30 Special Issue: Papers from the 32nd Annual Conference of the Internat ional 
Society for Clinical Biostatistics 30 December 2012.Pages 4321-4336  
Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A Phase I trial  of adoptive transfer of allogeneic 
natural killer cells in patients with advanced non-small cell lung cancer. Cancer  Immunol Immunother. 
2010;59:1781-9.  
Jing Y, Ni Z, Wu J, et al. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and 
the engineering of a non-cleavable version of the receptor in NK cells. PLoS One. 20 15;10:e0121788.  
Kaspers, G. 2014. How I treat paediatric relapsed acute myeloid leukaemia. Br J Hae matol 166: 636-
645.  
Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxi c cells with specificity for 
mouse Moloney leukemia cells. Specificity and distribution according to genotype.  Eur J Immunol. 
1975;5:112-7.   
Lajoie L, Congy-Jolivet N, Bolzec A, et al. ADAM17-mediated shedding of FcgRII IA on human NK 
cells: identification of the cleavage site and relationship with activation. J Immunol. 2014;192:741- 51.  
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release synd rome 
and neurological toxicity associated with immune effector cells. Biol Blood Marrow Tr ansplant. 
2019;25:625-38.  
Malavasi F, Deaglio S, Funaro A, et al. Evolution and Function of the ADP Ribosyl Cyclase/CD38 
Gene Family in Physiology and Pathology. Physiol Rev 88: 841 –886, 2008. 
Malmberg KJ, Carlsten M, Bjӧrklund A, et al. Natural killer cell -mediated immunosurveillance of human 
cancer. Semin Immunol. 2017;31:20-9.  
Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer  and in vivo expansion 
of human haploidentical NK cells in patients with cancer. Blood. 2005;105;3051-7.  
Mistry, J, Hellmich C, Moore J. Daratumumab Inhibits AML Metabolic Capacity an d Tumor Growth 
through Inhibition of CD38 Mediated Mitochondrial Transfer from Bone Marrow St romal Cells to Blasts 
in the Leukemic Microenvironment. Blood (2019) 134 (Supplement_1): 1385. 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 69 of 79 MT2020-33 Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and 
clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu –positive metastatic breast 
cancer. J Clin Oncol. 2008;26:1789-96.  
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T -cell therapy - assessment and 
management of toxicities. Nat Rev Clin Oncol. 2018;15:47-62.  
O’Quigley J, Shen LZ (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52: 
395-405. 
Pui, C. H., W. L. Carroll, S. Meshinchi, and R. J. Arceci. 2011.  Biology, risk stratification, and therapy 
of pediatric acute leukemias: an update. J Clin Oncol 29: 551-565. 
Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is r egulated by a 
disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121:3599-608.  
Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory- like natural killer cells exhibit 
enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123.  
Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-[ADDRESS_1176806] by [CONTACT_846389]-
15Rα. PNAS. 2006;103:9661 -71.  
Schuetz, C, Hoenig M, Moshous D, et.al. Daratumumab in life-threatening autoim mune hemolytic 
anemia following hematopoietic stem cell transplantation. Blood Adv 2: 2550-2553. 
Smyth MJ, Hayakawa Y, [COMPANY_005] K, et al. New aspects of natural-killer-cell survei llance and therapy 
of cancer. Nat Rev Cancer. 2002;2:850-61.  
Stoklasek TA, Schluns KS, and Lefrançois L. Combined IL-15/IL- 15Rα immunotherapy maximizes IL -
15 activity in vivo. J Immunol. 2006;177:6072-80. 
Tonn T, Schwabe D, Klingemann, et al. Treatment of patients with advanced cancer with the natural 
killer cell line NK-92. Cytotherapy. 2013;15:1563-70.  
Veluchamy JP, Kok N, van der Vliet HJ, et al. The rise of allogeneic natur al killer cells as a platform 
for cancer immunotherapy: recent innovations and future developments. Front Immun ol. 2017;8:631.  
Vogiatzi, F, Winterberg D, Lenk L, et.al. 2019. Daratumumab eradicates minimal residual disease in 
a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood 134: 713-716.  
Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27:5932-43 .  
Wang R, Jaw JJ, Stutzman NC, et al. Natural killer cell-produced IFN- γ and TNF -α induce target cell 
cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 2012;91:299-309.   
Wang W, Erbe A, Hank J, et al. NK cell-mediated antibody-dependent c ellular cytotoxicity in cancer 
immunotherapy. Front Immunol. 2015;6:368.  
Zhu H, Blum RH, Bjordahl R, et al. Pluripotent stem cell-derived NK cells w ith high-affinity 
noncleavable CD16a mediate improved antitumor activity. Blood 2020;135:399-410.    
Zohar S, Chevret S (2001). The continual reassessment method: comparison of Baye sian stoppi[INVESTIGATOR_846358]-ranging studies. Stat Med  20: 2827 –43. 
Zwaan, C. M., Kolb E. A., Reinhardt D, et.al. Collaborative Efforts Dr iving Progress in Pediatric Acute 
Myeloid Leukemia. J Clin Oncol 33: 2949-2962.   
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 70 of 79 MT2020-33 Appendix I – Karnofsky Performance Status Scale/Lansky Play –Performance Scale 
 
Karnofsky Performance Status Scale Definitions Rating (%) Criteria 
Able to carry on normal activity and to work; 
no special care needed. 100 Normal no complaints; no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
80 Normal activity with effort; some 
signs or symptoms of disease. 
Unable to work; able to live at home and care 
for most personal needs; varying amount of 
assistance needed. 70 Cares for self; unable to carry on 
normal activity or to do active work.  
[ADDRESS_1176807] of his 
personal needs. 
50 Requires considerable assistance 
and frequent medical care. 
Unable to care for self; requires equivalent of 
institutional or hospi[INVESTIGATOR_10422]; disease may be 
progressing rapi[INVESTIGATOR_375]. 40 Disabled; requires special care and 
assistance.  
30 Severely disabled; hospi[INVESTIGATOR_330114]. 
20 Very sick; hospi[INVESTIGATOR_62421]; active supportive 
treatment necessary.  
10 Moribund; fatal processes 
progressing rapi[INVESTIGATOR_375] 
0 Dead 
 
Ref  Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The Use of the Nitrogen Mustards in the Palliative 
Treatment of Carcinoma – with Particular Reference to Bronchogenic Carcinoma. Cancer. 1948;1(4):634-56.  
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 71 of 79 MT2020-33  
 
Lansky Play-Performance Scale for Pediatric Patients (<16 years of age) 
Rating Description 
100 Fully active, normal 
90 Minor restrictions with strenuous physical activity 
80 Active, but gets tired more quickly 
70 Both greater restriction of, and less time spent in, active play 
60 Up and around, but minimal active play; keeps busy with quieter activities 
50 Lying around much of the day, but gets dressed; no active play; participates in all quiet play and 
activities 
40 Mostly in bed; participates in quiet activities 
30 Stuck in bed; needs help even for quiet play 
20 Often sleepi[INVESTIGATOR_007]; play is entirely limited to very passive activities 
[ADDRESS_1176808] 1;60(7):1651-6.   
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 72 of 79 MT2020-33 Appendix II – [LOCATION_001] Heart Association (NYHA) Classification  
 
• Class I - No symptoms and no limitation in ordinary physical activity, e.g.  shortness of breath 
when walking, climbing stairs etc. 
 
• Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limita tion during 
ordinary activity. 
 
• Class III - Marked limitation in activity due to symptoms, even during l ess-than-ordinary 
activity, e.g. walking short distances (20 —100 m).Comfortable only at rest. 
 
• Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound  
patients. 
 
 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 73 of 79 MT2020-33 Appendix III - Risks Associated with Cyclophosphamide and Flud arabine 
 
Warnings and precautions ascribed to cyclophosphamide (CY) include: 
• Myelosuppression, immunosuppression, bone marrow failure, and infections (see next 
section) 
• Urinary tract and renal toxicity including hemorrhagic cystitis, pyelitis,  ureteritis, and 
hematuria 
− Urinary tract obstructions must be corrected prior to receipt of CY. 
• Cardiotoxicity including myocarditis, myopericarditis, pericardial effusion, arrythmias, and 
congestive heart failure, which may be fatal 
− Study participants should be closely monitored, especially those with risk factors fo r 
cardiotoxicity or pre-existing cardiac disease. 
• Pulmonary toxicity including pneumonitis, pulmonary fibrosis, and pulmonary veno-
occlusive disease leading to respi[INVESTIGATOR_1399] 
• Secondary malignancies 
• Veno-occlusive liver disease, which can be fatal 
• Embryo-fetal toxicity 
Adverse reactions reported most often include neutropenia, febrile neutropenia, fever , alopecia, 
nausea, vomiting, and diarrhea. 
 
For the complete safety profile of CY, as well as information regarding supportive care and 
management of associated toxicities, refer to the current prescribing information (U SPI). 
 
Warnings and precautions ascribed to fludarabine (FLU) include: 
• Severe bone marrow suppression, notably anemia, thrombocytopenia, and neutropenia 
(see below) 
• Transfusion-associated GvHD 
− Use only irradiated blood products for transfusions. 
• Severe CNS toxicity 
− Severe CNS toxicity was observed in patients treated at FLU doses of 96 mg/m2 for 
5-7 days. This toxicity was observed in ≤0.2% of patients treated at FLU doses of 25 
mg/m2  
− Infections 
• Renal insufficiency 
− The subject’s renal function should be monitored closely.  
• Tumor lysis syndrome ( Section 7.7 ) 
• Embryo-fetal toxicity 
Adverse reactions occurring in >30% of subjects treated with FLU include myel osuppression 
(neutropenia, thrombocytopenia, and anemia), fever, infection, nausea and vomiting, fat igue, 
anorexia, cough, and weakness. 
 
For the complete safety profile of fludarabine, as well as information rega rding supportive care and 
management of associated toxicities, refer to the current prescribing information (U SPI). 
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 74 of 79 MT2020-33 Risks of CY/FLU when given with adoptive cell therapi[INVESTIGATOR_014]: 
Some adoptive cell therapi[INVESTIGATOR_846359], such as CY and FLU  for 
conditioning, have been reported to cause myelosuppression (neutropenia, and/or thrombocy topenia), 
leukopenia, anemia, and in some cases, bone marrow failure. Hematologic cytopenias could be further 
compounded by [CONTACT_532853], concurrent illnesses, and concomitant 
medications. Close monitoring of complete blood count for the development of cytopenias and 
infections is strongly recommended. Management of cytopenias and infections, includ ing transfusion 
support, antimicrobial prophylaxis, and use of growth factors, should be done in accor dance with 
standard institutional practice.   
 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 75 of 79 MT2020-33 Appendix IV – European LeukemiaNet (ELN) Response Criteria in Acute 
Myelogenous Leukemia  
 
The European LeukemiaNet (ELN) response criteria in acute myelogenous leukemia (AML)  
(Döhner 2017 ) are presented below.  
 
Method of Assessment  
Assessments of response in AML are performed primarily through analysis of bone marrow 
biopsy/aspi[INVESTIGATOR_846360]. A single blood draw can be 
used for both hematology and disease response assessment if collected within 1 week of bone 
marrow biopsy with aspi[INVESTIGATOR_55523]. Radiographic methods may be used to document 
extramedullary disease.  
 
Categories of response, death due to treatment failure, and relapse are summarized in AI V-Table 1. 
Peripheral blood collection for tumor response assessment should be done on the same day as 
other tumor response assessment procedures, e.g., bone marrow biopsy/aspi[INVESTIGATOR_337].  
 
Testing for measurable residual disease (also known as minimal residual disease [MRD]) should b e 
done per institutional practice.  If done, the method with which MRD was tested,  
e.g., multiparameter flow cytometry (MFC) or molecular-based methodologies, e.g., reverse 
transcription polymerase chain reaction (RT-PCR), should be documented in the electronic C ase 
Report Form (eCRF). For subjects with extramedullary disease, the same radiographic method used 
to evaluate extramedullary disease at baseline should be used in subsequent tumor assessments. 
 
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 76 of 79 MT2020-33 AIV-Table 1 European LeukemiaNet Response Criteria in Acute Myelo genous 
Category Definition Comment 
Response 
Complete 
remission (CR) 
without minimal 
residual disease  
(CRMRD−)  If studied pretreatment, CR with negativity for a genetic marker 
by [CONTACT_937]-qPCR, or CR with negativity for MRD by [CONTACT_846390], and by 
[CONTACT_358722]; therefore, test used and 
sensitivity of the assay should be reported; 
analyses should be done in experienced 
laboratories (centralized diagnostics) 
Complete 
remission (CR) • Bone marrow blasts <5%; 
• Absence of circulating blasts and blasts with Auer rods; 
• Absence of extramedullary disease; c 
• ANC ≥1.0 × 10 e9/L (1000/µL); 
•Platelet count ≥100 × 10 e9/L (100,000/µL) MRD+ or unknown 
CR with 
incomplete 
hematologic 
recovery (CRi) All CR criteria except for residual neutropenia (<1.0 × 10e9/L 
[1000/µL]) or thrombocytopenia (<100 × 10e9/L [100,000/µL])  
Morphologic 
leukemia-free 
state (MLFS) • bone marrow blasts <5%; 
• Absence of blasts with Auer rods; 
• Absence of extramedullary disease; 
• No hematologic recovery required Marrow should not merely be "aplastic"; at 
least [ADDRESS_1176809] 10% 
Partial remission 
(PR) • All hematologic criteria of CR; 
• Decrease of bone marrow blast percentage to 5% to 25%; and 
• Decrease of pretreatment bone marrow blast percentage by [CONTACT_12697] 50%  
Stable disease 
(SD) Absence of CRMRD –, CR, CRi, PR, MLFS; and criteria for PD 
not met Period of stable disease should last at least 3 
months 
Progressive 
disease (PD) a, b Evidence for an increase in bone marrow blast percentage 
and/or absolute blast counts in blood. 
• 50% increase in marrow blasts over baseline (a minimum 
15% point increase is required in cases with <30% blasts at 
baseline; or persistent marrow blast percentage of >70%over 
at least 3 months; without at least a 100%improvement in 
ANC to an absolute level 
• (>0.5 × 10e9/L [500/ µL], and/or platelet count to >50 × 10e9/L 
[50,000/µL] non-transfused); or 
• >50% increase in peripheral blasts (WBC × %blasts) to >25 × 
10e9/L (>25,000/µL) (in the absence of differentiation 
syndrome); b or 
• New extramedullary disease c 
 • A confirmatory marrow assessment to 
document blast increase may be performed 
after at least 4 weeks; the date of 
progression should then be defined as of 
the first observation date 
• "Progressive disease" is usually 
accompanied by a decline in ANC and 
platelets and increased transfusion 
requirement and decline in performance 
status or increase in symptoms.  In these 
cases, a marrow assessment, and 
radiographic evaluation of extramedullary 
disease if applicable, should be performed. 
Death Due to Treatment Failure 
Death in Aplasia • Deaths occurring ≥7 days following completion of initial 
treatment while cytopenic; 
• With an aplastic or hypoplastic bone marrow obtained within 7 
days of death, without evidence of persistent leukemia  
Death from 
indeterminate 
cause • Deaths occurring before completion of therapy, or <7 days 
following its completion; or 
• Deaths occurring ≥7 days following completion of initial therapy 
with no blasts in the blood, but no bone marrow examination 
available  
Relapse 
Hematologic 
relapse  
(after CRMRD-, 
CR, CRi) Bone marrow blasts ≥5%; or reappearance of  blasts in the blood 
or development of exmedullary disease  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 77 of 79 MT2020-33 AIV-Table 1 European LeukemiaNet Response Criteria in Acute Myelo genous 
Category Definition Comment 
Molecular relapse 
(after CRMRD-) If studied pretreatment, reoccurrence of MRD as assessed by 
[CONTACT_937]–qPCR or by [CONTACT_846391], sensitivity of the assay, and 
cutoff values used must be reported; 
analyses should be done in experienced 
laboratories (centralized diagnostics) 
ANC, absolute neutrophil count; CR, complete remission; IDH, isocitrate dehydrogenase; MFC, multipara meterflow 
cytometry; MLFS, morphologic leukemia-free state; MRD, measurable residual disease (also known as mi nimal residual 
disease); RT-qPCR, real-time quantitative polymerase chain reaction; WBC, white blood cell . 
a “Progressive disease” is a new provisional category that is arbitrarily defined; the category aims at harmonizing  the 
various definitions used in different clinical trials. 
b Certain targeted therapi[INVESTIGATOR_014], e.g., those inhibiting mutant IDH proteins may cause a differentiation s yndrome, i.e., a 
transient increase in the percentage of bone marrow blasts and an absolute increase in blood blas ts; in the setting of 
therapy with such compounds, an increase in blasts may not necessarily indicate PD. 
c Radiographic evaluation of extramedullary disease per investigator discretion. The same radiograph ic modality used to 
assess extramedullary disease at baseline should be used in subsequent tumor response as sessments. 
Source: Döhner et al. 2017 . 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 78 of 79 MT2020-33 Appendix V: Initial Version of Study Schema, reflecting initial  lymphodepletion 
regimen and daratumumab schedule, effective 27-Jan-2021 to 24-Nov -2022) 
There is no Day 0 in this treatment plan . 
 
                                                            DLT Assessment Period through Day 29                                                                       
                                                                                                                                                                       Follow-up (months from  Day 1)  
                                                                CY/FLU                                                                                                           end             end  
                            D                    D                      FT538  D       FT538  D       FT538 D                   of DLT        of SR                                   
                 
                 
Study Day          -12                  -5      -4   -3           1      3            8    10          15    17                      29          42          3 mon  6 mon  9 mon  12 mon*      
No Day 0 
 
D:  DARZALEX FASPRO (1,800 mg daratumumab and 30,000 units hyaluronidas e) administered subcutaneously (subQ) once a week 
for 5 doses on Day -12, Day -5, and Day +3, Day +10, Day+17  
 
CY/FLU : Cyclophosphamide 300 mg/m2 and fludarabine (FLU) 25 mg/m2 administered by [CONTACT_766203] 2 consecutive days (Day -4 
and Day -3)   
 
FT538 : administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15  
 
All patients are monitored for dose limiting toxicities (DLTs) and  unacceptable toxicity using early stoppi[INVESTIGATOR_004] (SRs)  
Day 29 end of dose limiting toxicity (DLT) assessment (DLTs are defined on the next page and in Section 6.3.1  of the protocol) 
Day 42 end monitoring for excessive toxicity (SR events are defined on t he next page and in Section 6.3.2  of the protocol) 
 
*after the 12 month visit, follow-up transfers to the long-term follo w-up (LTFU) study  
 
Up to 5 dose levels of FT538 will be tested (including, a DL -1, only  used in event of DLT at DL 1):  
 
Dose Level (DL) Cohort FT538 cells/dose 
-1 5 x 107  
1 (start) 1 × 108  
2 3 × 108  
3 1 × 109  
4 1.5 × 109  
Each DL Cohort is separated by a minimum of 28 days (end of th e DLT period). A minimum of [ADDRESS_1176810] and the 2nd patient in 3 patient cohorts.  
 
  
CPRC #2020LS114:  FT538 with Daratumumab in Acute Myeloid Leukemia  
 
    
May 8, 2023 Page 79 of 79 MT2020-33 Appendix VI: Second Version of Study Schema, increased lymphodep letion with 
initial daratumumab schedule (Amended 11/24/2022, effective 11/24/2022 through  
03/20/2023)2 
There is no Day 0 in this treatment plan . 
 
                                                            DLT Assessment Period through Day 29                                                                       
                                                                                                                                                                       
                                                                                                                                                              assess         end            end  
                           D                      CY    CY     FT538     D    FT538      D     FT538     D      response   of DLT      of SR       Follow-up (months from  Day 1)  
                    
                    
Study Day          -12        -6    -5    -4   -3   -2     1          3         8        10         15    17          22              29         42         3 mon  6 mon  9 mon  12 mon*      
No Day 0 
 
D:  DARZALEX FASPRO (1,800 mg daratumumab and 30,000 units hyaluronidas e) administered subcutaneously (subQ) once a week 
for 5 doses on Day -12, Day -5, and Day +3, Day +10, Day+17  
 
FLU: fludarabine (FLU) 25 mg/m2 administered by [CONTACT_328926] 5 consecutive days, Day -6, Day - 5, Day -4, Day -3, and day -2.  
 
CY: Cyclophosphamide 60 mg/kg  administered by [CONTACT_846365] r 2 consecutive days, Day -4 and Day -3   
 
FT538 : administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15  
 
All patients are monitored for dose limiting toxicities (DLTs) and  unacceptable toxicity using early stoppi[INVESTIGATOR_004] (SRs)  
Day 29 end of dose limiting toxicity (DLT) assessment (DLTs are defined on the next page and in Section 6.3.1  of the protocol) 
Day 42 end monitoring for excessive toxicity (SR events are defined on t he next page and in Section 6.3.2  of the protocol) 
 
*after the 12 month visit, follow-up transfers to the long-term follo w-up (LTFU) study  
 
Up to 5 dose levels of FT538 will be tested (including, a DL -1, only  used in event of DLT at DL 1):  
 
Dose Level (DL) Cohort FT538 cells/dose 
-1 5 x 107  
1 (start) 1 × 108  
2 3 × 108  
3 1 × 109  
4 1.5 × 109  
Each DL Cohort is separated by a minimum of 28 days (end of th e DLT period). A minimum of [ADDRESS_1176811] and the 2nd patient in 3 patient cohorts.  
 
 
 
2 Subjects enrolled prior to 24-Nov-2022 received Cy-Flu lymphodeple tion on day -4 and day -3 only. See Appendix V for previous 
schema.  FLU 